```
     FILE 'HCAPLUS' ENTERED AT 18:01:21 ON 02 JUL 2008
L1        13810 S GUAR OR GALACTOMANNAN
L2           79 S FLUOROURACIL OF FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L3         2637 S LEUCOVORIN
L4            0 S L1 AND L2
L5            0 S L1 AND L2 AND L3
L6            0 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)
L7            0 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 18:01:32 ON 02 JUL 2008

     FILE 'HCAPLUS' ENTERED AT 18:02:04 ON 02 JUL 2008
L8        22775 S FLUOROURACIL OR FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L9           38 S L1 AND L8
L10           6 S L1 AND L8 AND L3
L11          18 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12           2 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'HCAPLUS' ENTERED AT 18:09:45 ON 02 JUL 2008
L13      235409 S INTERFERON OR INTERLEUKIN
L14          38 S L1 AND L13
L15           3 S L1 AND L3 AND L13
L16          23 S L14 AND (PY<2004 OR AY<2004 OR PRY<2004)
L17           1 S L15 AND (PY<2004 OR AY<2004 OR PRY<2004)
```

```
=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     1.89       1.89

FILE 'HCAPLUS' ENTERED AT 15:30:03 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Jul 2008  VOL 149 ISS 1
FILE LAST UPDATED: 1 Jul 2008  (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s guar or galactomannan

         11663 GUAR
          3183 GALACTOMANNAN
L1       13810 GUAR OR GALACTOMANNAN

=> s chemotherapeutic or fluorouracil or fluoropyrimidine  or methotrexate or
(ARA-c) or hydroxyurea or vinblastine or vincristine or vindesine or chlorambucil
or streptozocin or cisplatin or dacarbazine or doxorubicin or cyclophosphamide or
bisulfan or prednisone or paclitaxel

         22968 CHEMOTHERAPEUTIC
         21389 FLUOROURACIL
          1420 FLUOROPYRIMIDINE
         17958 METHOTREXATE
          6608 ARA
       3853008 C
          3127 ARA-C
                 (ARA(W)C)
          6783 HYDROXYUREA
          8154 VINBLASTINE
          9557 VINCRISTINE
          1215 VINDESINE
          2630 CHLORAMBUCIL
          1444 STREPTOZOCIN
         23605 CISPLATIN
          1508 DACARBAZINE
         18514 DOXORUBICIN
```

```
         19877 CYCLOPHOSPHAMIDE
            31 BISULFAN
          8061 PREDNISONE
         12210 PACLITAXEL
L2      129295 CHEMOTHERAPEUTIC OR FLUOROURACIL OR FLUOROPYRIMIDINE  OR METHOTR
               EXATE OR (ARA-C) OR HYDROXYUREA OR VINBLASTINE OR VINCRISTINE
               OR VINDESINE OR CHLORAMBUCIL OR STREPTOZOCIN OR CISPLATIN OR
               DACARBAZINE OR DOXORUBICIN OR CYCLOPHOSPHAMIDE OR BISULFAN OR
               PREDNISONE OR PACLITAXEL

=> s cancer or tumor or neopla?

        365017 CANCER
        457299 TUMOR
        549898 NEOPLA?
L3      841515 CANCER OR TUMOR OR NEOPLA?

=> s cytokine or leucovorin

        116509 CYTOKINE
          2637 LEUCOVORIN
L4      119110 CYTOKINE OR LEUCOVORIN

=> s intravenous or parenteral or intraarticular or subcutaneous or transdermal or
inhalation or transmucosal or rectal or intrathecal or topical

         43522 INTRAVENOUS
         23116 PARENTERAL
          1071 INTRAARTICULAR
         18795 SUBCUTANEOUS
         15739 TRANSDERMAL
         40356 INHALATION
          1276 TRANSMUCOSAL
         15462 RECTAL
          6894 INTRATHECAL
         50861 TOPICAL
L5      203405 INTRAVENOUS OR PARENTERAL OR INTRAARTICULAR OR SUBCUTANEOUS OR
               TRANSDERMAL OR INHALATION OR TRANSMUCOSAL OR RECTAL OR INTRATHEC
               AL OR TOPICAL

=> s l1 and l2

L6          102 L1 AND L2

=> s l1 and l3

L7          200 L1 AND L3

=> s l1 and l2 and l4

L8           12 L1 AND L2 AND L4

=> s l1 and l3 and l5

L9           38 L1 AND L3 AND L5

=> s l1 and l2 and l5

L10          20 L1 AND L2 AND L5

=> s l1 and l3 and l5
```

```
L11         38 L1 AND L3 AND L5

=> fiel stnguide

FIEL IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file stnguide
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                2.69       4.58

FILE 'STNGUIDE' ENTERED AT 15:30:20 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.06       4.64

FILE 'HCAPLUS' ENTERED AT 15:30:56 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Jul 2008  VOL 149 ISS 1
FILE LAST UPDATED: 1 Jul 2008  (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l8 and (PY<2003 or AY<2003 or PRY<2003)

      22935496 PY<2003
       4491181 AY<2003
       3959212 PRY<2003
L12           1 L8 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

```
=> s l9 and (PY<2003 or AY<2003 or PRY<2003)

      22935496 PY<2003
       4491181 AY<2003
       3959212 PRY<2003
L13          16 L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l10 and (PY<2003 or AY<2003 or PRY<2003)

      22935496 PY<2003
       4491181 AY<2003
       3959212 PRY<2003
L14          10 L10 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l11 and (PY<2003 or AY<2003 or PRY<2003)

      22935496 PY<2003
       4491181 AY<2003
       3959212 PRY<2003
L15          16 L11 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                2.69       7.33

FILE 'STNGUIDE' ENTERED AT 15:31:08 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.06       7.39

FILE 'HCAPLUS' ENTERED AT 15:31:43 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Jul 2008  VOL 149 ISS 1
FILE LAST UPDATED: 1 Jul 2008  (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l12 ti abs bib

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

AB The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.

AN 2007:175576 HCAPLUS <<LOGINID::20080702>>

DN 146:258964

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.

PA USA

SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20070036834	A1	20070215	US 2006-522126	20060915	<--
	AU 765269	B2	20030911	AU 2001-54192	20010703	<--
	US 20030049302	A1	20030313	US 2002-226667	20020821	<--
	US 6982091	B2	20060103			
	US 20060002966	A1	20060105	US 2005-208209	20050818	<--
	AU 2006292507	A1	20070329	AU 2006-292507	20060915	
	CA 2622746	A1	20070329	CA 2006-2622746	20060915	
	WO 2007035515	A2	20070329	WO 2006-US36087	20060915	
	WO 2007035515	A3	20070927			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

```
             KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2001-315877P      P     20010829  <--
     US 2002-226667       A1    20020821  <--
     US 2005-208209       A2    20050818
     US 2005-717680P      P     20050915
     AU 1998-76976        A3    19980610  <--
     WO 2006-US36087      W     20060915


=> d l13 1-16 ti abs bib


L13  ANSWER 1 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Foam prepared from nanoemulsions for administration to the skin
AB   The present invention provides a foamable composition for administration to the
     skin, body surface, body cavity or mucosal surface, e.g., the mucosa of
     the nose, mouth, eye, ear, respiratory system, vagina or rectum.  The
     foamable oil in water nano emulsion composition includes: (a) a nano oil
     globule system, comprising substantially of sub-micron oil globules; (b)
     about 0.1-5% by weight of at least one stabilizing agent, selected from the
     group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant,
     and (iii) a polymeric agent; and (c) a liquefied or compressed gas
     propellant at a concentration of 3-25% by weight of the total composition,
water and
     optional ingredients are added to complete the total mass to 100%.  Upon
     release from an aerosol container, the foamable composition forms and expanded
     foam suitable for topical administration.  The present invention
     further provides methods of treating, alleviating or preventing a disorder
     of the skin, body cavity or mucosal surface using such foamable compns.;
     and to methods of producing such foams having an improved bubble size.
AN   2008:708760  HCAPLUS <<LOGINID::20080702>>
TI   Foam prepared from nanoemulsions for administration to the skin
IN   Tamarkin, Dov; Besonov, Alex; Eini, Meir; Danziger, Jorge
PA   Foamix Ltd., Israel
SO   U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 389,742.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 26
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   US 20080138296      A1     20080612    US 2007-975621         20071019 <--
     WO 2004037225       A2     20040506    WO 2003-IB5527         20031024 <--
     WO 2004037225       A3     20041229
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20050069566      A1     20050331    US 2004-911367         20040804
     ZA 2005003298       A      20060830    ZA 2005-3298           20050425 <--
     US 20060140984      A1     20060629    US 2005-532618         20051222 <--
     US 20060233721      A1     20061019    US 2006-389742         20060327 <--
     AU 2006201878       A1     20070927    AU 2006-201878         20060504 <--
PRAI IL 2002-152486      A      20021025  <--
     US 2002-429546P     P      20021129  <--
```

US	2003-492385P	P	20030804
WO	2003-IB5527	W	20031024
US	2004-911367	A2	20040804
US	2005-717058P	P	20050914
US	2005-532618	A2	20051222
US	2006-389742	A2	20060327

L13 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant

AB The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compns. thereof. Thus, concns. of active agents (in wt%) in foamable compns. were as follows: hydrocortisone acetate 1, betamethasone valerate 0.12, clobetasol proprionate 0.05, acyclovir 5, ciclopirox 1, clindamycin 1-2, azelaic acid 15, metronidazol 0.25-2, diclofenac 1, tacrolimus 0.2, caffeine 5, clotrimazole 1, lidocaine base 2, terbinafine HCl 1, gentamycin 0.1, dexpanthenol 5, urea 5-10, ammonium lactate 12-17.5, povidone-iodine 10.

AN 2008:417770 HCAPLUS <<LOGINID::20080702>>

DN 148:410765

TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant

IN Freidman, Doron; Tamarkin, Dov; Feiman, Naomi; Schuz, David; Berman, Tal

PA Foamix Ltd., Israel

SO PCT Int. Appl., 115pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008038140	A2	20080403	WO 2007-IB3463	20070607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20070020213	A1	20070125	US 2006-488989	20060719 <--
	US 20070253911	A1	20071101	US 2007-717897	20070313 <--
PRAI	US 2006-811627P	P	20060607		
	US 2006-482596	A	20060707		
	US 2006-488989	A	20060719		
	US 2007-717897	A	20070313		
	IL 2002-152486	A	20021025	<--	
	US 2002-429546P	P	20021129	<--	
	US 2003-492385P	P	20030804		
	US 2003-497648P	P	20030825		
	WO 2003-IB5527	W	20031024		
	US 2003-530015P	P	20031216		
	US 2004-835505	A2	20040428		
	US 2004-911367	A2	20040804		

US 2004-922358	A2	20040820	
US 2005-78902	A2	20050311	
US 2005-124676	A2	20050509	
US 2005-700702P	P	20050719	
US 2005-532618	A2	20051222	
US 2006-781868P	P	20060313	
US 2007-897638P	P	20070126	
US 2007-899176P	P	20070202	

L13 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Foamable compositions, kits and drug delivery methods for treating hyperhidrosis
AB The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis. Thus, oil-in-water foamable composition comprised (in wt%): azelaic acid 15.00, mineral oil 5.60, iso-Pr palmitate 5.60, sorbitan stearate 2.00, PPG15-stearyl ether 1.00, stearic acid 0.85, glyceryl monostearate 0.45, xanthan gum 0.26, methocel K100M 0.26, preservative 0.25, propellant 10.00, and water to 100.
AN 2007:1237305 HCAPLUS <<LOGINID::20080702>>
DN 147:491650
TI Foamable compositions, kits and drug delivery methods for treating hyperhidrosis
IN Tamarkin, Dov; Eini, Meir; Zlatkis, Ella
PA Foamix Ltd., Israel
SO U.S. Pat. Appl. Publ., 38pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 26

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070253911	A1	20071101	US 2007-717897	20070313 <--
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050069566	A1	20050331	US 2004-911367	20040804
US 20050232869	A1	20051020	US 2005-78902	20050311 <--
ZA 2005003298	A	20060830	ZA 2005-3298	20050425 <--
US 20060140984	A1	20060629	US 2005-532618	20051222 <--
AU 2006201878	A1	20070927	AU 2006-201878	20060504 <--
US 20070292359	A1	20071220	US 2007-811140	20070607 <--
WO 2008038140	A2	20080403	WO 2007-IB3463	20070607

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

	US 20080044444	A1	20080221	US 2007-825406	20070705	<--
	US 20080152596	A1	20080626	US 2007-894767	20070820	
PRAI	IL 2002-152486	A	20021025	<--		
	US 2002-429546P	P	20021129	<--		
	US 2003-492385P	P	20030804			
	WO 2003-IB5527	W	20031024			
	US 2004-911367	A2	20040804			
	US 2005-78902	A2	20050311			
	US 2005-532618	A2	20051222			
	US 2006-781868P	P	20060313			
	US 2007-897638P	P	20070126			
	US 2007-899176P	P	20070202			
	US 2003-497648P	P	20030825			
	US 2003-530015P	P	20031216			
	US 2004-835505	A2	20040428			
	US 2004-922358	A2	20040820			
	US 2005-124676	A2	20050509			
	US 2005-696878P	P	20050706			
	US 2005-700702P	P	20050719			
	US 2006-811627P	P	20060607			
	US 2006-818634P	P	20060705			
	US 2006-481596	A2	20060706			
	US 2006-482596	A	20060707			
	US 2006-488989	A2	20060719			
	US 2007-653205	A2	20070112			
	US 2007-717897	A2	20070313			
	US 2007-811140	A1	20070607			

L13 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

AB The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.

AN 2007:175576 HCAPLUS <<LOGINID::20080702>>

DN 146:258964

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.
PA USA
SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20070036834	A1	20070215	US 2006-522126	20060915	<--
	AU 765269	B2	20030911	AU 2001-54192	20010703	<--
	US 20030049302	A1	20030313	US 2002-226667	20020821	<--
	US 6982091	B2	20060103			
	US 20060002966	A1	20060105	US 2005-208209	20050818	<--
	AU 2006292507	A1	20070329	AU 2006-292507	20060915	
	CA 2622746	A1	20070329	CA 2006-2622746	20060915	
	WO 2007035515	A2	20070329	WO 2006-US36087	20060915	
	WO 2007035515	A3	20070927			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
PRAI	US 2001-315877P	P	20010829	<--		
	US 2002-226667	A1	20020821	<--		
	US 2005-208209	A2	20050818			
	US 2005-717680P	P	20050915			
	AU 1998-76976	A3	19980610	<--		
	WO 2006-US36087	W	20060915			

L13 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Antibiotic kit and compositions
AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition
AN 2006:1256641 HCAPLUS <<LOGINID::20080702>>
DN 146:50262
TI Antibiotic kit and compositions
IN Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir
PA Foamix Ltd., Israel
SO U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20060269485	A1	20061130	US 2006-448490	20060607	<--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024	<--
	WO 2004037225	A3	20041229			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US 20050069566	A1	20050331	US 2004-911367	20040804	
	US 20060140984	A1	20060629	US 2005-532618	20051222	<--
	AU 2006339311	A2	20070907	AU 2006-339311	20060607	
	AU 2006339311	A1	20070907			
	CA 2611577	A1	20070907	CA 2006-2611577	20060607	
	WO 2007099396	A2	20070907	WO 2006-IB3975	20060607	
	WO 2007099396	A3	20080313			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
	EP 1919449	A2	20080514	EP 2006-847249	20060607	
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS					
	US 20070292355	A1	20071220	US 2007-732547	20070404	<--
	WO 2008075207	A2	20080626	WO 2007-IB4459	20070404	
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
PRAI	US 2002-429546P	P	20021129	<--		
	US 2003-492385P	P	20030804			
	WO 2003-IB5527	W	20031024			
	US 2004-911367	A2	20040804			
	US 2005-688244P	P	20050607			
	US 2005-532618	A2	20051222			

IL	2002-152486	A	20021025	<--
US	2003-497648P	P	20030825	
US	2003-530015P	P	20031216	
US	2004-835505	A2	20040428	
US	2004-922358	A2	20040820	
US	2005-41921	A2	20050124	
US	2006-789186P	P	20060404	
US	2006-448490	A2	20060607	
WO	2006-IB3975	W	20060607	
US	2006-861620P	P	20061129	
US	2007-880434P	P	20070112	

L13 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Foamable oil in water emulsion composition comprising polymer

AB The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1% to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. For example, emulsion composition was prepared comprising mineral oil 5.6%, iso-Pr myristate 5.6%, glyceryl monostearate 0.45%, PEG-40 stearate 2.6%, stearyl alc. 0.85%, Xanthan gum 0.26%, methocel K100M 0.26%, Polysorbate 80 0.90%, water 74.88%, preservative 0.60 and propellant 8%.

AN 2006:1094143 HCAPLUS <<LOGINID::20080702>>

DN 145:426012

TI Foamable oil in water emulsion composition comprising polymer

IN Tamarkin, Dov; Friedman, Doron; Besonov, Alex; Eini, Meir

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 26

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20060233721	A1	20061019	US 2006-389742	20060327 <--
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050069566	A1	20050331	US 2004-911367	20040804
ZA 2005003298	A	20060830	ZA 2005-3298	20050425 <--
US 20060140984	A1	20060629	US 2005-532618	20051222 <--
AU 2006201878	A1	20070927	AU 2006-201878	20060504 <--
WO 2007102052	A2	20070913	WO 2006-IB4170	20060914
WO 2007102052	A3	20080103		

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
            KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
            MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
            RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
    US 20080138296        A1     20080612     US 2007-975621         20071019 <--
PRAI IL 2002-152486       A      20021025   <--
    US 2002-429546P       P      20021129   <--
    US 2003-492385P       P      20030804
    WO 2003-IB5527        W      20031024
    US 2004-911367        A2     20040804
    US 2005-717058P       P      20050914
    US 2005-532618        A2     20051222
    US 2006-389742        A      20060327

L13  ANSWER 7 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Nanoparticulate megestrol formulations containing surface stabilizer
AB   The present invention is directed to nanoparticulate compns. comprising
     megestrol.  The megestrol particles of the composition have an effective
average
     particle size of <2000 nm.  Thus, a formulation contained megestrol 5,
     HPMC 1, and dioctyl sodium sulfosuccinate 0.05%.
AN   2005:36425  HCAPLUS <<LOGINID::20080702>>
DN   142:120565
TI   Nanoparticulate megestrol formulations containing surface stabilizer
IN   Hovey, Douglas; Pruitt, John; Ryde, Tuula
PA   Elan Pharma International Ltd., USA
SO   U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 412,669.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 20050008707      A1     20050113    US 2004-878623         20040629 <--
     US 20030219490      A1     20031127    US 2003-412669         20030414 <--
     US 7101576          B2     20060905
     US 20040105889      A1     20040603    US 2003-420927         20030423 <--
     CA 2508301          A1     20040617    CA 2003-2508301        20030423 <--
     WO 2004050059       A1     20040617    WO 2003-US12660        20030423 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003231071        A1     20040623    AU 2003-231071         20030423 <--
     EP 1613276           A1     20060111    EP 2003-724196         20030423
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
```

```
     JP 2006510726         T     20060330    JP 2004-570751          20030423 <--
     EP 1935407            A1    20080625    EP 2008-4947            20030423 <--
        R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
     US 20050233001        A1    20051020    US 2005-93149           20050330 <--
     US 20080152585        A1    20080626    US 2007-979253          20071031 <--
PRAI US 2002-371680P       P     20020412  <--
     US 2002-430348P       P     20021203  <--
     US 2003-412669        A2    20030414
     EP 2003-724196        A3    20030423
     US 2003-420927        A1    20030423
     WO 2003-US12660       W     20030423
     US 2004-878623        A1    20040629

L13  ANSWER 8 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Liquid dosage compositions of stable nanoparticulate drugs
AB   The present invention relates to liquid dosage compns. of stable
     nanoparticulate drugs.  The liquid dosage compns. of the invention include
     osmotically active crystal growth inhibitors that stabilize the
     nanoparticulate active agents against crystal and particle size growth of
     the drug.  Thus, an aqueous nanoparticulate colloidal dispersion (NCD)
     comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate
     0.464% by weight was prepared by milling for 3.8 h under high energy milling
     conditions.  The final mean particle size (by weight) of the drug particles
     was 161 nm.  The concentrated NCD was then diluted with preserved water and
     glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0%
     drug.
AN   2004:60341  HCAPLUS <<LOGINID::20080702>>
DN   140:117406
TI   Liquid dosage compositions of stable nanoparticulate drugs
IN   Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura
     J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu,
     Shuqian
PA   Elan Pharma International, Ltd, Ire.
SO   PCT Int. Appl., 68 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 18
     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     --------------        ----   --------    --------------------    --------
PI   WO 2004006959         A1     20040122    WO 2003-US22187         20030716 <--
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2492488            A1     20040122    CA 2003-2492488         20030716 <--
     AU 2003261167         A1     20040202    AU 2003-261167          20030716 <--
     EP 1551457            A1     20050713    EP 2003-764723          20030716 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005536512         T      20051202    JP 2004-521891          20030716 <--
PRAI US 2002-396530P       P      20020716  <--
     WO 2003-US22187       W      20030716
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Combination of immediate release and controlled release pharmaceuticals
AB Disclosed are compns. exhibiting a combination of immediate release and controlled release characteristics. The compns. comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least 1 active ingredient having a microparticulate particle size. Using a math. model, pharmacokinetic profiles were developed after single oral doses of a pharmaceutical formulation containing a drug having a single defined particle size. Small particles dissolve faster than larger particles, but that they also decay more rapidly. As a consequence, larger drug particles provide the longest blood plasma levels, although these same particles exhibit slow dissoln.
AN 2003:300863 HCAPLUS <<LOGINID::20080702>>
DN 138:326560
TI Combination of immediate release and controlled release pharmaceuticals
IN Cooper, Eugene R.; Ruddy, Stephen B.
PA USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003030872	A2	20030417	WO 2002-US32314	20021011 <--
	WO 2003030872	A3	20030731		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463495	A1	20030417	CA 2002-2463495	20021011 <--
	AU 2002334939	A1	20030422	AU 2002-334939	20021011 <--
	US 20030137067	A1	20030724	US 2002-268928	20021011 <--
	US 6908626	B2	20050621		
	EP 1443912	A2	20040811	EP 2002-800993	20021011 <--
	EP 1443912	B1	20070829		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005508939	T	20050407	JP 2003-533905	20021011 <--
	AT 371442	T	20070915	AT 2002-800993	20021011 <--
	ES 2292848	T3	20080316	ES 2002-800993	20021011 <--
PRAI	US 2001-328405P	P	20011012	<--	
	WO 2002-US32314	W	20021011	<--	

L13 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Treatment of inflammatory skin conditions
AB The invention relates to the use of one or more antimicrobial metals, most preferably silver, preferably formed with atomic disorder, and preferably in a nanocryst. form,for the treatment of inflammatory skin conditions. The nanocryst. antimicrobial metal of choice may be used in the form of a nanocryst. coating of one or more antimicrobial metals, a nanocryst.

powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocryst. powder or coating of one or more antimicrobial metals. Thus, a com. CM-cellulose/pectin gel (DuoDERM) was combined with nanocryst. silver powder prepared to produce a gel with 0.1%silver. A logarithmic reduction test was performed as follows in the gel by using Pseudomonas aeruginosa. The logarithmic reduction for this mixture was 6.2, indicating a significant bactericidal effect.

AN 2002:832637 HCAPLUS <<LOGINID::20080702>>
DN 137:316115
TI Treatment of inflammatory skin conditions
IN Burrell, Robert Edward; Yin, Hua Qing
PA Nucryst Pharmaceuticals Corp., Can.
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 24

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002085387	A2	20021031	WO 2002-CA549	20020423	<--
	WO 2002085387	A3	20030116			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US 20020192298	A1	20021219	US 2001-840637	20010423	<--
	US 7008647	B2	20060307			
	CA 2445740	A1	20021031	CA 2002-2445740	20020423	<--
	AU 2002252881	A1	20021105	AU 2002-252881	20020423	<--
	AU 2002252881	B2	20070726			
	EP 1383522	A2	20040128	EP 2002-721904	20020423	<--
	EP 1383522	B1	20060405			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2004529930	T	20040930	JP 2002-582960	20020423	<--
	AT 322274	T	20060415	AT 2002-721904	20020423	<--
	ES 2261659	T3	20061116	ES 2002-721904	20020423	<--
	US 20060083777	A1	20060420	US 2005-284506	20051122	<--
PRAI	US 2001-285884P	P	20010423	<--		
	US 2001-840637	A	20010423	<--		
	WO 2002-CA549	W	20020423	<--		

L13 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of aqueous clear solution dosage forms with bile acids
AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a
range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain
a pharmaceutical compound, such as insulin, heparin, bismuth compds.,

amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

AN 2002:185616 HCAPLUS <<LOGINID::20080702>>
DN 136:252482
TI Preparation of aqueous clear solution dosage forms with bile acids
IN Yoo, Seo Hong
PA USA
SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20020031558	A1	20020314	US 2001-778154	20010205	<--
	US 7303768	B2	20071204			
	US 6251428	B1	20010626	US 1999-357549	19990720	<--
	US 20030186933	A1	20031002	US 2002-309603	20021204	<--
	US 7166299	B2	20070123			
	US 20050158408	A1	20050721	US 2004-996945	20041124	<--
	AU 2004325203	A1	20060601	AU 2004-325203	20041124	
	CA 2588168	A1	20060601	CA 2004-2588168	20041124	
	EP 1819318	A1	20070822	EP 2004-812094	20041124	
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
	CN 101065110	A	20071031	CN 2004-80044467	20041124	
	BR 2004019213	A	20071218	BR 2004-19213	20041124	
	JP 2008521800	T	20080626	JP 2007-543006	20041124	
	AU 2006203315	A1	20060824	AU 2006-203315	20060803	<--
	US 20070072828	A1	20070329	US 2006-522162	20060915	<--
	IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612	
	KR 2007098821	A	20071005	KR 2007-714361	20070622	
	US 20080057133	A1	20080306	US 2007-934505	20071102	<--
PRAI	US 1998-94069P	P	19980724	<--		
	US 1999-357549	A2	19990720	<--		
	US 2000-180268P	P	20000204	<--		
	AU 2001-36685	A3	20010205	<--		
	US 2001-778154	A3	20010205	<--		
	US 2004-996945	A2	20041124			
	WO 2004-US39507	A	20041124			

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Tannins in method of isolating mucilaginous polysaccharides and uses for the polysaccharides thus obtained
AB The present invention provides a method of isolating mucilaginous polysaccharides from plants, cereals, cell cultures, or fungi such as mushrooms known to have mucilaginous or protein-bound polysaccharides with desirable biol. properties. The mucilaginous polysaccharides present in aqueous solution or tissue exts. are treated with tannins to form a complex which is then separated from the solution The complex is then treated one or more times with either solvents or other substances in solution to remove the bounded tannins from the complex thereby and releasing the isolated polysaccharide. The polysaccharides prepared according to the present method retain properties that are substantially similar to those of the

native polysaccharide as it is found in the resp. plant or cell. The polysaccharides thus prepared are used in a variety of products, e.g., in cosmetics, pharmaceuticals, and food products. This process is particularly suitable for isolating acetylated mannose polymers from aloe plants and beta glucans.

AN 2000:493312 HCAPLUS <<LOGINID::20080702>>
DN 133:101738
TI Tannins in method of isolating mucilaginous polysaccharides and uses for the polysaccharides thus obtained
IN Vittori, Natale
PA Vito-Mannan Polysaccharide L.L.C., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041541	A2	20000720	WO 2000-US759	20000111 <--
	WO 2000041541	A3	20011115		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2328092	A1	20000720	CA 2000-2328092	20000111 <--
	EP 1144456	A2	20011017	EP 2000-904309	20000111 <--
	EP 1144456	A3	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6482942	B1	20021119	US 2000-481111	20000111 <--
	MX 2000PA09966	A	20011211	MX 2000-PA9966	20001011 <--
PRAI	US 1999-115619P	P	19990112	<--	
	WO 2000-US759	W	20000111	<--	

L13 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Improved formulation for topical non-invasive application in vivo
AB A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided that the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over is enabled. The formulation also contains 1 antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.
AN 2000:456858 HCAPLUS <<LOGINID::20080702>>
DN 133:94512
TI Improved formulation for topical non-invasive application in

vivo
IN Cevc, Gregor
PA Idea Innovative Dermale Applikationen G.m.b.H., Germany
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000038653	A1	20000706	WO 1998-EP8421	19981223	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	CA 2356080	A1	20000706	CA 1998-2356080	19981223	<--
	AU 9925137	A	20000731	AU 1999-25137	19981223	<--
	AU 770803	B2	20040304			
	EP 1140021	A1	20011010	EP 1998-966846	19981223	<--
	EP 1140021	B1	20040804			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	BR 9816113	A	20011023	BR 1998-16113	19981223	<--
	HU 2001004424	A2	20020328	HU 2001-4424	19981223	<--
	HU 2001004424	A3	20021228			
	JP 2002533379	T	20021008	JP 2000-590607	19981223	<--
	EE 200100342	A	20021015	EE 2001-342	19981223	<--
	RU 2207844	C2	20030710	RU 2001-120008	19981223	<--
	AT 272391	T	20040815	AT 1998-966846	19981223	<--
	ES 2226203	T3	20050316	ES 1998-966846	19981223	<--
	PL 193824	B1	20070330	PL 1967-3494	19981223	<--
	HR 2001000309	A1	20020630	HR 2001-309	20010502	<--
	HR 2001000309	B1	20050630			
	NO 2001003164	A	20010822	NO 2001-3164	20010622	<--
	US 20020064524	A1	20020530	US 2001-887493	20010622	<--
	US 7175850	B2	20070213			
	MX 2001PA06424	A	20020604	MX 2001-PA6424	20010622	<--
	HK 1040629	A1	20050128	HK 2002-102230	20020323	<--
	US 20070184114	A1	20070809	US 2006-638091	20061212	<--
PRAI	WO 1998-EP8421	A	19981223	<--		
	US 2001-887493	A1	20010622	<--		

OS MARPAT 133:94512
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
AB The disclosed formulation is comprised of: (a) 0.1-5 weight dehydroepiandrosterone; (b) 0.5-3% acrylic gel, 1-3% guar gum, or 1-3% cellulose-derived gel; and optionally other ingredients such as hydrophilic gels, estradiol, vitamins, progesterone, minoxidil, hyaluronidase, vasoprotectants, plant exts., etc. The formulation has various pharmacol. applications, e.g. for treating menstrual disorders, mammary and gynecol. neoplasms, lipodystrophy, panniculopathy, circulatory disorders, bruises, muscular pain, obesity, diabetes, osteoporosis, aging, etc.

AN 1997:204223 HCAPLUS <<LOGINID::20080702>>
DN 126:190952
OREF 126:36787a,36790a
TI Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
IN Cabo Soler, Jose; Calderon Gomez, Jesus; Palacios Gil-Antunano, Santiago
PA Spain
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA Spanish
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703676	A1	19970206	WO 1996-ES153	19960719 <--
	W: AU, BR, CA, CN, JP, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ES 2098193	A1	19970416	ES 1995-1471	19950721 <--
	ES 2098193	B1	19971201		
	AU 9664196	A	19970218	AU 1996-64196	19960719 <--
PRAI	ES 1995-1471	A	19950721	<--	
	WO 1996-ES153	W	19960719	<--	

L13 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
AB Delivery to the colon of fatty acids, especially short-chain fatty acids (SCFA), can be effected by covalently linking SCFA to a carrier, that is preferably a carbohydrate, by an ester link. The SCFA is protected by its link with the carbohydrate through the small intestine, and where the carbohydrate is digestible in the small intestine such as a digestible starch, the starch can also be protected from digestion in the small intestine by the substitution. Levels of SCFA such as acetate, propionate and butyrate may be elevated to have beneficial effects in the prevention of colonic disorders, such as rectal cancer, diverticulitis, colitis, diarrhea and constipation.
AN 1995:756390 HCAPLUS <<LOGINID::20080702>>
DN 123:142666
OREF 123:25401a,25404a
TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
IN Anisson, Geoffrey; Topping, David; Illman, Richard
PA Commonwealth Scientific and Industrial Research Organisation, Australia
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9513801	A1	19950526	WO 1994-AU713	19941117 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2176719	A1	19950526	CA 1994-2176719	19941117 <--
	CA 2176719	C	20070918		
	AU 9481368	A	19950606	AU 1994-81368	19941117 <--
	AU 695906	B2	19980827		

	EP 730447	A1	19960911	EP 1995-900575	19941117 <--
	EP 730447	B1	20020220		
	R: CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 09505060	T	19970520	JP 1994-514114	19941117 <--
	JP 4071823	B2	20080402	JP 1995-514114	19941117 <--
	US 5840860	A	19981124	US 1996-646294	19960905 <--
PRAI	AU 1993-2454	A	19931117	<--	
	WO 1994-AU713	W	19941117	<--	

L13 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Method for preparing diagnostic slide coated with immunoreactive substance-sensitized latex and water-soluble polymer
AB The method comprises coating the slide with a reagent layer containing immunoreactive substance (e.g. antibody or antigen)-sensitized latex, water-soluble polymer (e.g. PVP), and optionally a water-soluble natural compound (e.g. cyclodextrin), followed by natural drying to produce a stable and redissolvable coating. Thus, monoclonal anti-mannan antibody was prepared, immobilized on latex, coated on a slide together with PVP, and used for detecting mannan derived from Candida tropicalis.
AN 1993:599163 HCAPLUS <<LOGINID::20080702>>
DN 119:199163
OREF 119:35405a,35408a
TI Method for preparing diagnostic slide coated with immunoreactive substance-sensitized latex and water-soluble polymer
IN Kondo, Kenji; Yoshimura, Makoto; Fujii, Masahiko
PA Kureha Chemical Ind Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05196623	A	19930806	JP 1992-171730	19920606 <--
	JP 2631796	B2	19970716		
PRAI	JP 1991-176213	A1	19910620	<--	

=> d l14 1-10 ti abs bib

L14 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
AB The present invention relates to a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixts. thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixts. thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant. Thus, a foaming vehicle composition comprised (i) an oil phase containing diisopropyl adipate (DISPA) 20.00, benzyl alc. 2.00, oleyl alc. 20.00, PPG 15 stearyl ether 2.00, sorbitan stearate 2.00, and stearyl alc. 3.00, and (ii) a water phase containing hydroxypropyl Me cellulose 0.15, xanthan gum 0.15, sucrose ester 3.00, propylene glycol

17.70, and water 30.00%, resp.

AN 2008:226051 HCAPLUS <<LOGINID::20080702>>

DN 148:269446

TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

IN Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20080044444	A1	20080221	US 2007-825406	20070705	<--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024	<--
	WO 2004037225	A3	20041229			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US 20050031547	A1	20050210	US 2004-835505	20040428	
	US 20050069566	A1	20050331	US 2004-911367	20040804	
	AU 2004313285	A1	20050929	AU 2004-313285	20041216	
	US 20050232869	A1	20051020	US 2005-78902	20050311	<--
	ZA 2005003298	A	20060830	ZA 2005-3298	20050425	<--
	US 20060140984	A1	20060629	US 2005-532618	20051222	<--
	AU 2006201878	A1	20070927	AU 2006-201878	20060504	<--
	US 20070280891	A1	20071206	US 2006-645444	20061226	
	US 20070292461	A1	20071220	US 2007-653205	20070112	
	US 20070253911	A1	20071101	US 2007-717897	20070313	<--
	WO 2008038147	A2	20080403	WO 2007-IB3759	20070705	
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	US 20080050317	A1	20080228	US 2007-894668	20070820	
PRAI	IL 2002-152486	A	20021025	<--		
	US 2002-429546P	P	20021129	<--		
	US 2003-492385P	P	20030804			
	WO 2003-IB5527	W	20031024			
	US 2003-530015P	P	20031216			
	US 2004-835505	A2	20040428			
	US 2004-911367	A2	20040804			
	US 2005-78902	A2	20050311			
	US 2005-532618	A2	20051222			
	US 2006-818634P	P	20060705			
	US 2007-653205	A2	20070112			

US 2007-717897	A2	20070313	
US 2005-679020P	P	20050509	
US 2006-781868P	P	20060313	
US 2006-784793P	P	20060321	
US 2006-430599	A2	20060509	
US 2007-897638P	P	20070126	
US 2007-899176P	P	20070202	

L14 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

AB The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.

AN 2007:175576 HCAPLUS <<LOGINID::20080702>>

DN 146:258964

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.

PA USA

SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 20070036834	A1	20070215	US 2006-522126	20060915	<--
AU 765269	B2	20030911	AU 2001-54192	20010703	<--
US 20030049302	A1	20030313	US 2002-226667	20020821	<--
US 6982091	B2	20060103			
US 20060002966	A1	20060105	US 2005-208209	20050818	<--
AU 2006292507	A1	20070329	AU 2006-292507	20060915	
CA 2622746	A1	20070329	CA 2006-2622746	20060915	
WO 2007035515	A2	20070329	WO 2006-US36087	20060915	
WO 2007035515	A3	20070927			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI	US 2001-315877P	P	20010829	<--
	US 2002-226667	A1	20020821	<--
	US 2005-208209	A2	20050818	
	US 2005-717680P	P	20050915	
	AU 1998-76976	A3	19980610	<--
	WO 2006-US36087	W	20060915	

L14 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antibiotic kit and compositions

AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition

AN 2006:1256641 HCAPLUS <<LOGINID::20080702>>

DN 146:50262

TI Antibiotic kit and compositions

IN Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060269485	A1	20061130	US 2006-448490	20060607 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050069566	A1	20050331	US 2004-911367	20040804
	US 20060140984	A1	20060629	US 2005-532618	20051222 <--
	AU 2006339311	A2	20070907	AU 2006-339311	20060607
	AU 2006339311	A1	20070907		
	CA 2611577	A1	20070907	CA 2006-2611577	20060607
	WO 2007099396	A2	20070907	WO 2006-IB3975	20060607
	WO 2007099396	A3	20080313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

```
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     EP 1919449          A2   20080514    EP 2006-847249         20060607
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
            BA, HR, MK, RS
     US 20070292355      A1   20071220    US 2007-732547         20070404 <--
     WO 2008075207       A2   20080626    WO 2007-IB4459         20070404
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
            GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
            KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG,
            MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
            RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
            TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2002-429546P      P    20021129  <--
     US 2003-492385P      P    20030804
     WO 2003-IB5527       W    20031024
     US 2004-911367       A2   20040804
     US 2005-688244P      P    20050607
     US 2005-532618       A2   20051222
     IL 2002-152486       A    20021025  <--
     US 2003-497648P      P    20030825
     US 2003-530015P      P    20031216
     US 2004-835505       A2   20040428
     US 2004-922358       A2   20040820
     US 2005-41921        A2   20050124
     US 2006-789186P      P    20060404
     US 2006-448490       A2   20060607
     WO 2006-IB3975       W    20060607
     US 2006-861620P      P    20061129
     US 2007-880434P      P    20070112

L14  ANSWER 4 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Liquid dosage compositions of stable nanoparticulate drugs
AB   The present invention relates to liquid dosage compns. of stable
     nanoparticulate drugs.  The liquid dosage compns. of the invention include
     osmotically active crystal growth inhibitors that stabilize the
     nanoparticulate active agents against crystal and particle size growth of
     the drug.  Thus, an aqueous nanoparticulate colloidal dispersion (NCD)
     comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate
     0.464% by weight was prepared by milling for 3.8 h under high energy milling
     conditions.  The final mean particle size (by weight) of the drug particles
     was 161 nm.  The concentrated NCD was then diluted with preserved water and
     glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0%
     drug.
AN   2004:60341  HCAPLUS <<LOGINID::20080702>>
DN   140:117406
TI   Liquid dosage compositions of stable nanoparticulate drugs
IN   Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura
     J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu,
     Shuqian
PA   Elan Pharma International, Ltd, Ire.
SO   PCT Int. Appl., 68 pp.
```

```
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 18
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2004006959        A1    20040122    WO 2003-US22187        20030716 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2492488            A1    20040122    CA 2003-2492488        20030716 <--
     AU 2003261167         A1    20040202    AU 2003-261167         20030716 <--
     EP 1551457            A1    20050713    EP 2003-764723         20030716 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005536512         T     20051202    JP 2004-521891         20030716 <--
PRAI US 2002-396530P       P     20020716  <--
     WO 2003-US22187       W     20030716
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14  ANSWER 5 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Preparation of aqueous clear solution dosage forms with bile acids
AB   Compns. for pharmaceutical and other uses comprise clear aqueous solns. of
     bile acids which do not form any detectable ppts. over selected ranges of
     pH values of the aqueous solution  The compns. comprise (i) water, (ii) a bile
     acid component in the form of a bile acid, bile acid salt, or a bile acid
     conjugated with an amine by an amide linkage; and (iii) either or both an
     aqueous soluble starch conversion product and an aqueous soluble non-starch
     polysaccharide.  The composition remains in solution without forming a
precipitate over a
     range of pH values and, according to one embodiment, remains in solution for
     all pH values obtainable in an aqueous system.  The composition may further
contain
     a pharmaceutical compound, such as insulin, heparin, bismuth compds.,
     amantadine and rimantadine.  For example, solution dosage forms that did not
     show any precipitation at any pH were prepared containing ursodeoxycholic acid
(UDCA) 22
     g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g,
     bismuth citrate 4 g, citric acid or lactic acid as needed, and purified
     water to make 1 L.
AN   2002:185616  HCAPLUS <<LOGINID::20080702>>
DN   136:252482
TI   Preparation of aqueous clear solution dosage forms with bile acids
IN   Yoo, Seo Hong
PA   USA
SO   U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   US 20020031558       A1    20020314    US 2001-778154         20010205 <--
```

	US 7303768	B2	20071204		
	US 6251428	B1	20010626	US 1999-357549	19990720 <--
	US 20030186933	A1	20031002	US 2002-309603	20021204 <--
	US 7166299	B2	20070123		
	US 20050158408	A1	20050721	US 2004-996945	20041124 <--
	AU 2004325203	A1	20060601	AU 2004-325203	20041124
	CA 2588168	A1	20060601	CA 2004-2588168	20041124
	EP 1819318	A1	20070822	EP 2004-812094	20041124
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101065110	A	20071031	CN 2004-80044467	20041124
	BR 2004019213	A	20071218	BR 2004-19213	20041124
	JP 2008521800	T	20080626	JP 2007-543006	20041124
	AU 2006203315	A1	20060824	AU 2006-203315	20060803 <--
	US 20070072828	A1	20070329	US 2006-522162	20060915 <--
	IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
	KR 2007098821	A	20071005	KR 2007-714361	20070622
	US 20080057133	A1	20080306	US 2007-934505	20071102 <--
PRAI	US 1998-94069P	P	19980724	<--	
	US 1999-357549	A2	19990720	<--	
	US 2000-180268P	P	20000204	<--	
	AU 2001-36685	A3	20010205	<--	
	US 2001-778154	A3	20010205	<--	
	US 2004-996945	A2	20041124		
	WO 2004-US39507	A	20041124		

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Anti-itch patch containing analgesics, anesthetics, or corticosteroids
AB An adhesive anti-itch patch comprising a flexible backing having a front side and a back side and a therapeutic formulation positioned on the entire surface or on a portion of the front side of the backing is described. The therapeutic formulation includes a medicament, i.e., an antipruritic agent, such as an analgesic, an anesthetic, or a corticosteroid, useful for treating a condition associated with an insect bite, a rash, a skin irritation, poison ivy, poison oak, an inflammatory skin condition, or poison sumac; and a pressure sensitive adhesive. A method for treating a skin condition associated with itching includes applying to the skin surface an adhesive patch of the present invention. For example, therapeutic formulation contained (by weight) lidocaine 2.5%, camphor 3.0%, propylene glycol 8.4%, polyethylene glycol 0.7%, fragrance 0.5%, glycerin 42.4%, Aloe vera 1.0%, algin 22.5%, water 4.0%, and acrylic ester copolymer adhesive 15.0%.
AN 2001:434847 HCAPLUS <<LOGINID::20080702>>
DN 135:66217
TI Anti-itch patch containing analgesics, anesthetics, or corticosteroids
IN Rolf, David; Buseman, Teri
PA Lectec Corporation, USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041746	A1	20010614	WO 2000-US33498	20001211 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001041745 A1 20010614 WO 2000-US12970 20000512 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6469227 B1 20021022 US 2000-569783 20000512 <--
PRAI US 1999-170041P P 19991210 <--
US 2000-569783 A 20000512 <--
WO 2000-US12970 W 20000512 <--
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI A method for the improvement of transport across adaptable semi-permeable barriers
AB The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier, the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate; said penetrants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetd. area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier. Highly adaptable complex droplets (ultradeformable vesicles or Transfersomes) were prepared containing soybean phosphatidylcholine, Na cholate, 3H-labeled DPPC and phosphate buffer.
AN 2001:31308 HCAPLUS <<LOGINID::20080702>>
DN 134:91147
TI A method for the improvement of transport across adaptable semi-permeable barriers
IN Cevc, Gregor
PA Idea Innovative Dermale Applikationen G.m.b.H., Germany
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001001962	A1	20010111	WO 1999-EP4659	19990705 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				

```
            ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
            CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9954096          A     20010122    AU 1999-54096          19990705 <--
     CA 2375157          A1    20010111    CA 2000-2375157        20000705 <--
     WO 2001001963       A1    20010111    WO 2000-EP6367         20000705 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1189598          A1    20020327    EP 2000-947939         20000705 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     HU 2002001454       A2    20021228    HU 2002-1454           20000705 <--
     HU 2002001454       A3    20040528
     JP 2003503442       T     20030128    JP 2001-507458         20000705 <--
     EE 200200008        A     20030415    EE 2002-8              20000705 <--
     AU 779765           B2    20050210    AU 2000-61557          20000705 <--
     RU 2260445          C2    20050920    RU 2002-101651         20000705 <--
     HR 2001000881       A1    20030831    HR 2001-881            20011127 <--
     IN 2001DN01133      A     20050311    IN 2001-DN1133         20011206 <--
     NO 2002000032       A     20020305    NO 2002-32             20020104 <--
     US 20030099694      A1    20030529    US 2002-37480          20020104 <--
     MX 2002PA00053      A     20030721    MX 2002-PA53           20020107 <--
     US 20050123897      A1    20050609    US 2004-984450         20041108 <--
     IN 2005DN03651      A     20070824    IN 2005-DN3651         20050818 <--
PRAI WO 1999-EP4659      A     19990705  <--
     WO 2000-EP6367      W     20000705  <--
     IN 2001-DN1133      A3    20011206  <--
     US 2002-37480       A1    20020104  <--
RE.CNT  5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14  ANSWER 8 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Improved formulation for topical non-invasive application in
     vivo
AB   A formulation comprises mol. arrangements capable of penetrating pores in
     a barrier, owing to penetrant adaptability, despite the fact that the average
     diameter of the pores is smaller than the average penetrant diameter, provided
that
     the penetrants can transport agents or cause permeation through the pores
     after penetrants have entered pores.  The formulation comprises at least 1
     consistency builder in an amount that increases the formulation to maximally
     5 Nm/s so that spreading over is enabled.  The formulation also contains 1
     antioxidant in an amount that reduces the increase of oxidation index to <100%
     per 6 mo and/or at least 1 microbicide in an amount that reduces the
     bacterial count of 1 million germs added/g of total mass of the
     formulation to <100 in the case of aerobic bacteria, to <10 in the case of
     entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or
     Staphilococcus aureus, after a period of 4 days.  Thus, a composition contained
     soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30,
     benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate
     buffer 9000 mg.
AN   2000:456858  HCAPLUS <<LOGINID::20080702>>
DN   133:94512
TI   Improved formulation for topical non-invasive application in
     vivo
```

IN Cevc, Gregor
PA Idea Innovative Dermale Applikationen G.m.b.H., Germany
SO PCT Int. Appl., 73 pp.
    CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000038653	A1	20000706	WO 1998-EP8421	19981223	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	CA 2356080	A1	20000706	CA 1998-2356080	19981223	<--
	AU 9925137	A	20000731	AU 1999-25137	19981223	<--
	AU 770803	B2	20040304			
	EP 1140021	A1	20011010	EP 1998-966846	19981223	<--
	EP 1140021	B1	20040804			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	BR 9816113	A	20011023	BR 1998-16113	19981223	<--
	HU 2001004424	A2	20020328	HU 2001-4424	19981223	<--
	HU 2001004424	A3	20021228			
	JP 2002533379	T	20021008	JP 2000-590607	19981223	<--
	EE 200100342	A	20021015	EE 2001-342	19981223	<--
	RU 2207844	C2	20030710	RU 2001-120008	19981223	<--
	AT 272391	T	20040815	AT 1998-966846	19981223	<--
	ES 2226203	T3	20050316	ES 1998-966846	19981223	<--
	PL 193824	B1	20070330	PL 1967-3494	19981223	<--
	HR 2001000309	A1	20020630	HR 2001-309	20010502	<--
	HR 2001000309	B1	20050630			
	NO 2001003164	A	20010822	NO 2001-3164	20010622	<--
	US 20020064524	A1	20020530	US 2001-887493	20010622	<--
	US 7175850	B2	20070213			
	MX 2001PA06424	A	20020604	MX 2001-PA6424	20010622	<--
	HK 1040629	A1	20050128	HK 2002-102230	20020323	<--
	US 20070184114	A1	20070809	US 2006-638091	20061212	<--
PRAI	WO 1998-EP8421	A	19981223	<--		
	US 2001-887493	A1	20010622	<--		

OS MARPAT 133:94512
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
          ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
AB Gas and gaseous precursor filled microspheres, and foams provide novel topical and s.c. delivery vehicles for various active ingredients, including drugs and cosmetics. Gas and gaseous precursor filled microcapsules were prepared from dipalmitoylphosphatidylcholine.
AN 1998:207280 HCAPLUS <<LOGINID::20080702>>
DN 128:275101
OREF 128:54369a,54372a
TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IN Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David

PA Imarx Pharmaceutical Corp., USA
SO U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 307,305.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5733572	A	19980331	US 1994-346426	19941129	<--
	US 5088499	A	19920218	US 1990-569828	19900820	<--
	WO 9109629	A1	19910711	WO 1990-US7500	19901219	<--
	W: CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE					
	JP 05502675	T	19930513	JP 1991-503276	19901219	<--
	JP 3309356	B2	20020729			
	AT 180170	T	19990615	AT 1991-902857	19901219	<--
	ES 2131051	T3	19990716	ES 1991-902857	19901219	<--
	CA 2069759	C	20070116	CA 1990-2069759	19901219	<--
	US 5228446	A	19930720	US 1991-717084	19910618	<--
	WO 9222247	A1	19921223	WO 1992-US2615	19920331	<--
	W: AU, CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE					
	AU 9220020	A	19930112	AU 1992-20020	19920331	<--
	AU 667471	B2	19960328			
	JP 06508364	T	19940922	JP 1993-500847	19920331	<--
	JP 3456584	B2	20031014			
	EP 616508	A1	19940928	EP 1992-912456	19920331	<--
	EP 616508	B1	20010718			
	EP 616508	B2	20040929			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE					
	AT 203148	T	20010815	AT 1992-912456	19920331	<--
	ES 2159280	T3	20011001	ES 1992-912456	19920331	<--
	CA 2110491	C	20070724	CA 1992-2110491	19920331	<--
	US 5469854	A	19951128	US 1993-76239	19930611	<--
	US 5580575	A	19961203	US 1993-76250	19930611	<--
	US 5348016	A	19940920	US 1993-88268	19930707	<--
	US 5542935	A	19960806	US 1993-160232	19931130	<--
	US 5585112	A	19961217	US 1993-159687	19931130	<--
	US 5769080	A	19980623	US 1994-199462	19940222	<--
	WO 9428874	A1	19941222	WO 1994-US5633	19940519	<--
	W: AU, CA, CN, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	US 5773024	A	19980630	US 1994-307305	19940916	<--
	CA 2177713	A1	19950608	CA 1994-2177713	19941130	<--
	WO 9515118	A1	19950608	WO 1994-US13817	19941130	<--
	W: AU, CA, CN, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 740528	A1	19961106	EP 1995-908414	19941130	<--
	EP 740528	B1	20030326			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	JP 09506098	T	19970617	JP 1995-515763	19941130	<--
	AT 235228	T	20030415	AT 1995-908414	19941130	<--
	US 5571497	A	19961105	US 1995-468056	19950606	<--
	CN 1180310	A	19980429	CN 1996-193069	19960327	<--
	CN 1102045	B	20030226			
	US 6001335	A	19991214	US 1996-665719	19960618	<--
	US 5935553	A	19990810	US 1996-758179	19961125	<--
	US 6743779	B1	20040601	US 1997-841169	19970429	<--
	US 5985246	A	19991116	US 1997-888426	19970708	<--
	AU 9856271	A	19980507	AU 1998-56271	19980224	<--
	AU 713127	B2	19991125			

AU	9888405	A	19981203	AU 1998-88405	19981012 <--
AU	731072	B2	20010322		
HK	1013625	A1	20000420	HK 1998-114978	19981223 <--
AU	9910043	A	19990304	AU 1999-10043	19990104 <--
GR	3036877	T3	20020131	GR 2001-401740	20011011 <--
PRAI US	1989-455707	B2	19891222	<--	
US	1990-569828	A2	19900820	<--	
US	1991-716899	B2	19910618	<--	
US	1991-717084	A2	19910618	<--	
US	1993-76239	A2	19930611	<--	
US	1993-76250	A2	19930611	<--	
US	1993-159674	B2	19931130	<--	
US	1993-159687	A2	19931130	<--	
US	1993-160232	A2	19931130	<--	
US	1994-307305	A2	19940916	<--	
WO	1990-US7500	W	19901219	<--	
US	1991-716793	A	19910618	<--	
US	1991-750877	A3	19910826	<--	
US	1992-818069	A3	19920108	<--	
WO	1992-US2615	A	19920331	<--	
US	1992-967974	A3	19921027	<--	
US	1993-17683	A3	19930212	<--	
US	1993-18112	B3	19930217	<--	
US	1993-85608	A3	19930630	<--	
US	1993-88268	A3	19930707	<--	
US	1993-163039	A3	19931206	<--	
US	1994-212553	B2	19940311	<--	
AU	1994-70416	A3	19940519	<--	
US	1994-346426	A	19941129	<--	
AU	1995-21850	A3	19941130	<--	
WO	1994-US13817	W	19941130	<--	
US	1995-395683	A3	19950228	<--	
US	1995-468056	A3	19950606	<--	
US	1995-471250	A3	19950606	<--	
US	1996-640554	B2	19960501	<--	
US	1996-665719	A3	19960618	<--	
US	1997-785661	B2	19970117	<--	

RE.CNT 314 THERE ARE 314 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Bioadhesive-wound healing composition
AB The present invention pertains to therapeutic bioadhesive-wound healing compns. useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compns. comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsatd. fatty acids. The therapeutic bioadhesive-wound healing compns. may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compns. and the pharmaceutical products in which the compns. may be used.
AN 1996:367739 HCAPLUS <<LOGINID::20080702>>
DN 125:19043
OREF 125:3725a,3728a
TI Bioadhesive-wound healing composition
IN Leung, Sau-Hung S.; Martin, Alain

```
PA   Warner-Lambert Company, USA
SO   PCT Int. Appl., 159 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 28
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9606640          A1     19960307    WO 1995-US8568         19950707 <--
         W:  AU, CA, JP, MX, NZ, SG
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     US 5658956          A      19970819    US 1995-445824         19950522 <--
     AU 9530045          A      19960322    AU 1995-30045          19950707 <--
     AU 707353           B2     19990708
     EP 779820           A1     19970625    EP 1995-926209         19950707 <--
         R:  BE, CH, DE, DK, ES, FR, GB, GR, IT, LI
     JP 10505057         T      19980519    JP 1996-508729         19950707 <--
     ZA 9507245          A      19970630    ZA 1995-7245           19950829 <--
PRAI US 1994-298521      A      19940830    <--
     US 1995-445824      A      19950522    <--
     US 1991-663500      B1     19910301    <--
     US 1993-53922       B2     19930426    <--
     WO 1995-US8568      W      19950707    <--


=> d l15 1-16 ti abs bib


L15  ANSWER 1 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Foam prepared from nanoemulsions for administration to the skin
AB   The present invention provides a foamable composition for administration to the
     skin, body surface, body cavity or mucosal surface, e.g., the mucosa of
     the nose, mouth, eye, ear, respiratory system, vagina or rectum.  The
     foamable oil in water nano emulsion composition includes: (a) a nano oil
     globule system, comprising substantially of sub-micron oil globules; (b)
     about 0.1-5% by weight of at least one stabilizing agent, selected from the
     group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant,
     and (iii) a polymeric agent; and (c) a liquefied or compressed gas
     propellant at a concentration of 3-25% by weight of the total composition,
water and
     optional ingredients are added to complete the total mass to 100%.  Upon
     release from an aerosol container, the foamable composition forms and expanded
     foam suitable for topical administration.  The present invention
     further provides methods of treating, alleviating or preventing a disorder
     of the skin, body cavity or mucosal surface using such foamable compns.;
     and to methods of producing such foams having an improved bubble size.
AN   2008:708760  HCAPLUS <<LOGINID::20080702>>
TI   Foam prepared from nanoemulsions for administration to the skin
IN   Tamarkin, Dov; Besonov, Alex; Eini, Meir; Danziger, Jorge
PA   Foamix Ltd., Israel
SO   U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 389,742.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 26
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   US 20080138296      A1     20080612    US 2007-975621         20071019 <--
     WO 2004037225       A2     20040506    WO 2003-IB5527         20031024 <--
     WO 2004037225       A3     20041229
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
```

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 20050069566	A1	20050331	US 2004-911367	20040804	
	ZA 2005003298	A	20060830	ZA 2005-3298	20050425	<--
	US 20060140984	A1	20060629	US 2005-532618	20051222	<--
	US 20060233721	A1	20061019	US 2006-389742	20060327	<--
	AU 2006201878	A1	20070927	AU 2006-201878	20060504	<--
PRAI	IL 2002-152486	A	20021025	<--		
	US 2002-429546P	P	20021129	<--		
	US 2003-492385P	P	20030804			
	WO 2003-IB5527	W	20031024			
	US 2004-911367	A2	20040804			
	US 2005-717058P	P	20050914			
	US 2005-532618	A2	20051222			
	US 2006-389742	A2	20060327			

L15 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant

AB The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compns. thereof. Thus, concns. of active agents (in wt%) in foamable compns. were as follows: hydrocortisone acetate 1, betamethasone valerate 0.12, clobetasol proprionate 0.05, acyclovir 5, ciclopirox 1, clindamycin 1-2, azelaic acid 15, metronidazol 0.25-2, diclofenac 1, tacrolimus 0.2, caffeine 5, clotrimazole 1, lidocaine base 2, terbinafine HCl 1, gentamycin 0.1, dexpanthenol 5, urea 5-10, ammonium lactate 12-17.5, povidone-iodine 10.

AN 2008:417770 HCAPLUS <<LOGINID::20080702>>

DN 148:410765

TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant

IN Freidman, Doron; Tamarkin, Dov; Feiman, Naomi; Schuz, David; Berman, Tal

PA Foamix Ltd., Israel

SO PCT Int. Appl., 115pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008038140	A2	20080403	WO 2007-IB3463	20070607

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,

GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

	US 20070020213	A1	20070125	US 2006-488989	20060719 <--
	US 20070253911	A1	20071101	US 2007-717897	20070313 <--
PRAI	US 2006-811627P	P	20060607		
	US 2006-482596	A	20060707		
	US 2006-488989	A	20060719		
	US 2007-717897	A	20070313		
	IL 2002-152486	A	20021025	<--	
	US 2002-429546P	P	20021129	<--	
	US 2003-492385P	P	20030804		
	US 2003-497648P	P	20030825		
	WO 2003-IB5527	W	20031024		
	US 2003-530015P	P	20031216		
	US 2004-835505	A2	20040428		
	US 2004-911367	A2	20040804		
	US 2004-922358	A2	20040820		
	US 2005-78902	A2	20050311		
	US 2005-124676	A2	20050509		
	US 2005-700702P	P	20050719		
	US 2005-532618	A2	20051222		
	US 2006-781868P	P	20060313		
	US 2007-897638P	P	20070126		
	US 2007-899176P	P	20070202		

L15 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Foamable compositions, kits and drug delivery methods for treating hyperhidrosis

AB The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis. Thus, oil-in-water foamable composition comprised (in wt%): azelaic acid 15.00, mineral oil 5.60, iso-Pr palmitate 5.60, sorbitan stearate 2.00, PPG15-stearyl ether 1.00, stearic acid 0.85, glyceryl monostearate 0.45, xanthan gum 0.26, methocel K100M 0.26, preservative 0.25, propellant 10.00, and water to 100.

AN 2007:1237305 HCAPLUS <<LOGINID::20080702>>

DN 147:491650

TI Foamable compositions, kits and drug delivery methods for treating hyperhidrosis

IN Tamarkin, Dov; Eini, Meir; Zlatkis, Ella

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 38pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070253911	A1	20071101	US 2007-717897	20070313 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050069566 A1 20050331 US 2004-911367 20040804
US 20050232869 A1 20051020 US 2005-78902 20050311 <--
ZA 2005003298 A 20060830 ZA 2005-3298 20050425 <--
US 20060140984 A1 20060629 US 2005-532618 20051222 <--
AU 2006201878 A1 20070927 AU 2006-201878 20060504 <--
US 20070292359 A1 20071220 US 2007-811140 20070607 <--
WO 2008038140 A2 20080403 WO 2007-IB3463 20070607

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

US 20080044444 A1 20080221 US 2007-825406 20070705 <--
US 20080152596 A1 20080626 US 2007-894767 20070820
PRAI IL 2002-152486 A 20021025 <--
US 2002-429546P P 20021129 <--
US 2003-492385P P 20030804
WO 2003-IB5527 W 20031024
US 2004-911367 A2 20040804
US 2005-78902 A2 20050311
US 2005-532618 A2 20051222
US 2006-781868P P 20060313
US 2007-897638P P 20070126
US 2007-899176P P 20070202
US 2003-497648P P 20030825
US 2003-530015P P 20031216
US 2004-835505 A2 20040428
US 2004-922358 A2 20040820
US 2005-124676 A2 20050509
US 2005-696878P P 20050706
US 2005-700702P P 20050719
US 2006-811627P P 20060607
US 2006-818634P P 20060705
US 2006-481596 A2 20060706
US 2006-482596 A 20060707
US 2006-488989 A2 20060719
US 2007-653205 A2 20070112
US 2007-717897 A2 20070313
US 2007-811140 A1 20070607

L15 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

AB The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.

AN 2007:175576 HCAPLUS <<LOGINID::20080702>>

DN 146:258964

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.

PA USA

SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20070036834	A1	20070215	US 2006-522126	20060915	<--
	AU 765269	B2	20030911	AU 2001-54192	20010703	<--
	US 20030049302	A1	20030313	US 2002-226667	20020821	<--
	US 6982091	B2	20060103			
	US 20060002966	A1	20060105	US 2005-208209	20050818	<--
	AU 2006292507	A1	20070329	AU 2006-292507	20060915	
	CA 2622746	A1	20070329	CA 2006-2622746	20060915	
	WO 2007035515	A2	20070329	WO 2006-US36087	20060915	
	WO 2007035515	A3	20070927			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
PRAI	US 2001-315877P	P	20010829	<--		
	US 2002-226667	A1	20020821	<--		
	US 2005-208209	A2	20050818			
	US 2005-717680P	P	20050915			
	AU 1998-76976	A3	19980610	<--		
	WO 2006-US36087	W	20060915			

L15 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antibiotic kit and compositions

AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The

assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition

AN 2006:1256641 HCAPLUS <<LOGINID::20080702>>

DN 146:50262

TI Antibiotic kit and compositions

IN Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060269485	A1	20061130	US 2006-448490	20060607 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050069566	A1	20050331	US 2004-911367	20040804
	US 20060140984	A1	20060629	US 2005-532618	20051222 <--
	AU 2006339311	A2	20070907	AU 2006-339311	20060607
	AU 2006339311	A1	20070907		
	CA 2611577	A1	20070907	CA 2006-2611577	20060607
	WO 2007099396	A2	20070907	WO 2006-IB3975	20060607
	WO 2007099396	A3	20080313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1919449	A2	20080514	EP 2006-847249	20060607
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	US 20070292355	A1	20071220	US 2007-732547	20070404 <--
	WO 2008075207	A2	20080626	WO 2007-IB4459	20070404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,				

GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

PRAI	US 2002-429546P	P	20021129	<--
	US 2003-492385P	P	20030804	
	WO 2003-IB5527	W	20031024	
	US 2004-911367	A2	20040804	
	US 2005-688244P	P	20050607	
	US 2005-532618	A2	20051222	
	IL 2002-152486	A	20021025	<--
	US 2003-497648P	P	20030825	
	US 2003-530015P	P	20031216	
	US 2004-835505	A2	20040428	
	US 2004-922358	A2	20040820	
	US 2005-41921	A2	20050124	
	US 2006-789186P	P	20060404	
	US 2006-448490	A2	20060607	
	WO 2006-IB3975	W	20060607	
	US 2006-861620P	P	20061129	
	US 2007-880434P	P	20070112	

L15 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Foamable oil in water emulsion composition comprising polymer

AB The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1% to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. For example, emulsion composition was prepared comprising mineral oil 5.6%, iso-Pr myristate 5.6%, glyceryl monostearate 0.45%, PEG-40 stearate 2.6%, stearyl alc. 0.85%, Xanthan gum 0.26%, methocel K100M 0.26%, Polysorbate 80 0.90%, water 74.88%, preservative 0.60 and propellant 8%.

AN 2006:1094143 HCAPLUS <<LOGINID::20080702>>

DN 145:426012

TI Foamable oil in water emulsion composition comprising polymer

IN Tamarkin, Dov; Friedman, Doron; Besonov, Alex; Eini, Meir

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060233721	A1	20061019	US 2006-389742	20060327 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20050069566	A1	20050331	US 2004-911367	20040804	
ZA	2005003298	A	20060830	ZA 2005-3298	20050425	<--
US	20060140984	A1	20060629	US 2005-532618	20051222	<--
AU	2006201878	A1	20070927	AU 2006-201878	20060504	<--
WO	2007102052	A2	20070913	WO 2006-IB4170	20060914	
WO	2007102052	A3	20080103			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US	20080138296	A1	20080612	US 2007-975621	20071019	<--
PRAI IL	2002-152486	A	20021025	<--		
US	2002-429546P	P	20021129	<--		
US	2003-492385P	P	20030804			
WO	2003-IB5527	W	20031024			
US	2004-911367	A2	20040804			
US	2005-717058P	P	20050914			
US	2005-532618	A2	20051222			
US	2006-389742	A	20060327			

L15 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Nanoparticulate megestrol formulations containing surface stabilizer
AB The present invention is directed to nanoparticulate compns. comprising megestrol. The megestrol particles of the composition have an effective average
particle size of <2000 nm. Thus, a formulation contained megestrol 5, HPMC 1, and dioctyl sodium sulfosuccinate 0.05%.
AN 2005:36425 HCAPLUS <<LOGINID::20080702>>
DN 142:120565
TI Nanoparticulate megestrol formulations containing surface stabilizer
IN Hovey, Douglas; Pruitt, John; Ryde, Tuula
PA Elan Pharma International Ltd., USA
SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 412,669.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20050008707	A1	20050113	US 2004-878623	20040629	<--
	US 20030219490	A1	20031127	US 2003-412669	20030414	<--
	US 7101576	B2	20060905			
	US 20040105889	A1	20040603	US 2003-420927	20030423	<--

```
     CA 2508301          A1    20040617    CA 2003-2508301        20030423 <--
     WO 2004050059       A1    20040617    WO 2003-US12660        20030423 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
           GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
           LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
           PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
           TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
           KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
           FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
           BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003231071       A1    20040623    AU 2003-231071         20030423 <--
     EP 1613276          A1    20060111    EP 2003-724196         20030423
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006510726       T     20060330    JP 2004-570751         20030423 <--
     EP 1935407          A1    20080625    EP 2008-4947           20030423 <--
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
           IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
     US 20050233001      A1    20051020    US 2005-93149          20050330 <--
     US 20080152585      A1    20080626    US 2007-979253         20071031 <--
PRAI US 2002-371680P     P     20020412  <--
     US 2002-430348P     P     20021203  <--
     US 2003-412669      A2    20030414
     EP 2003-724196      A3    20030423
     US 2003-420927      A1    20030423
     WO 2003-US12660     W     20030423
     US 2004-878623      A1    20040629

L15  ANSWER 8 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Liquid dosage compositions of stable nanoparticulate drugs
AB   The present invention relates to liquid dosage compns. of stable
     nanoparticulate drugs.  The liquid dosage compns. of the invention include
     osmotically active crystal growth inhibitors that stabilize the
     nanoparticulate active agents against crystal and particle size growth of
     the drug.  Thus, an aqueous nanoparticulate colloidal dispersion (NCD)
     comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate
     0.464% by weight was prepared by milling for 3.8 h under high energy milling
     conditions.  The final mean particle size (by weight) of the drug particles
     was 161 nm.  The concentrated NCD was then diluted with preserved water and
     glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0%
     drug.
AN   2004:60341  HCAPLUS <<LOGINID::20080702>>
DN   140:117406
TI   Liquid dosage compositions of stable nanoparticulate drugs
IN   Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura
     J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu,
     Shuqian
PA   Elan Pharma International, Ltd, Ire.
SO   PCT Int. Appl., 68 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 18
     PATENT NO.          KIND    DATE        APPLICATION NO.        DATE
     ------------------  ----    --------    --------------------   --------
PI   WO 2004006959       A1      20040122    WO 2003-US22187        20030716 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
           GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
```

```
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2492488          A1    20040122    CA 2003-2492488        20030716 <--
    AU 2003261167       A1    20040202    AU 2003-261167         20030716 <--
    EP 1551457          A1    20050713    EP 2003-764723         20030716 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    JP 2005536512       T     20051202    JP 2004-521891         20030716 <--
PRAI US 2002-396530P    P     20020716  <--
    WO 2003-US22187     W     20030716
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15  ANSWER 9 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Combination of immediate release and controlled release pharmaceuticals
AB   Disclosed are compns. exhibiting a combination of immediate release and
     controlled release characteristics.  The compns. comprise at least one
     poorly soluble active ingredient having a nanoparticulate particle size, at
     least one surface stabilizer adsorbed onto the surface of the
     nanoparticulate active agent particles, and at least 1 active ingredient
     having a microparticulate particle size.  Using a math. model,
     pharmacokinetic profiles were developed after single oral doses of a
     pharmaceutical formulation containing a drug having a single defined particle
     size.  Small particles dissolve faster than larger particles, but that
     they also decay more rapidly.  As a consequence, larger drug particles
     provide the longest blood plasma levels, although these same particles
     exhibit slow dissoln.
AN   2003:300863  HCAPLUS <<LOGINID::20080702>>
DN   138:326560
TI   Combination of immediate release and controlled release pharmaceuticals
IN   Cooper, Eugene R.; Ruddy, Stephen B.
PA   USA
SO   PCT Int. Appl., 45 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2003030872       A2     20030417    WO 2002-US32314        20021011 <--
     WO 2003030872       A3     20030731
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
            CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2463495          A1     20030417    CA 2002-2463495        20021011 <--
     AU 2002334939       A1     20030422    AU 2002-334939         20021011 <--
     US 20030137067      A1     20030724    US 2002-268928         20021011 <--
     US 6908626          B2     20050621
     EP 1443912          A2     20040811    EP 2002-800993         20021011 <--
```

```
     EP 1443912          B1    20070829
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005508939       T     20050407   JP 2003-533905        20021011 <--
     AT 371442           T     20070915   AT 2002-800993        20021011 <--
     ES 2292848          T3    20080316   ES 2002-800993        20021011 <--
PRAI US 2001-328405P     P     20011012  <--
     WO 2002-US32314     W     20021011  <--

L15  ANSWER 10 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Treatment of inflammatory skin conditions
AB   The invention relates to the use of one or more antimicrobial metals, most
     preferably silver, preferably formed with atomic disorder, and preferably in
     a nanocryst. form,for the treatment of inflammatory skin conditions.  The
     nanocryst. antimicrobial metal of choice may be used in the form of a
     nanocryst. coating of one or more antimicrobial metals, a nanocryst.
     powder of one or more antimicrobial metals, or a solution containing dissolved
     species from a nanocryst. powder or coating of one or more antimicrobial
     metals.  Thus, a com. CM-cellulose/pectin gel (DuoDERM) was combined with
     nanocryst. silver powder prepared to produce a gel with 0.1%silver.  A
     logarithmic reduction test was performed as follows in the gel by using
     Pseudomonas aeruginosa.  The logarithmic reduction for this mixture was 6.2,
     indicating a significant bactericidal effect.
AN   2002:832637  HCAPLUS <<LOGINID::20080702>>
DN   137:316115
TI   Treatment of inflammatory skin conditions
IN   Burrell, Robert Edward; Yin, Hua Qing
PA   Nucryst Pharmaceuticals Corp., Can.
SO   PCT Int. Appl., 58 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 24
     PATENT NO.          KIND   DATE       APPLICATION NO.       DATE
     ---------------     ----   --------   -------------------   --------
PI   WO 2002085387       A2     20021031   WO 2002-CA549         20020423 <--
     WO 2002085387       A3     20030116
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20020192298       A1     20021219   US 2001-840637        20010423 <--
     US 7008647           B2     20060307
     CA 2445740           A1     20021031   CA 2002-2445740       20020423 <--
     AU 2002252881        A1     20021105   AU 2002-252881        20020423 <--
     AU 2002252881        B2     20070726
     EP 1383522           A2     20040128   EP 2002-721904        20020423 <--
     EP 1383522           B1     20060405
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004529930        T      20040930   JP 2002-582960        20020423 <--
     AT 322274            T      20060415   AT 2002-721904        20020423 <--
     ES 2261659           T3     20061116   ES 2002-721904        20020423 <--
     US 20060083777       A1     20060420   US 2005-284506        20051122 <--
PRAI US 2001-285884P      P      20010423  <--
     US 2001-840637       A      20010423  <--
```

WO 2002-CA549 W 20020423 <--

L15 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of aqueous clear solution dosage forms with bile acids
AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.
AN 2002:185616 HCAPLUS <<LOGINID::20080702>>
DN 136:252482
TI Preparation of aqueous clear solution dosage forms with bile acids
IN Yoo, Seo Hong
PA USA
SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020031558	A1	20020314	US 2001-778154	20010205 <--
	US 7303768	B2	20071204		
	US 6251428	B1	20010626	US 1999-357549	19990720 <--
	US 20030186933	A1	20031002	US 2002-309603	20021204 <--
	US 7166299	B2	20070123		
	US 20050158408	A1	20050721	US 2004-996945	20041124 <--
	AU 2004325203	A1	20060601	AU 2004-325203	20041124
	CA 2588168	A1	20060601	CA 2004-2588168	20041124
	EP 1819318	A1	20070822	EP 2004-812094	20041124
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101065110	A	20071031	CN 2004-80044467	20041124
	BR 2004019213	A	20071218	BR 2004-19213	20041124
	JP 2008521800	T	20080626	JP 2007-543006	20041124
	AU 2006203315	A1	20060824	AU 2006-203315	20060803 <--
	US 20070072828	A1	20070329	US 2006-522162	20060915 <--
	IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
	KR 2007098821	A	20071005	KR 2007-714361	20070622
	US 20080057133	A1	20080306	US 2007-934505	20071102 <--
PRAI	US 1998-94069P	P	19980724	<--	
	US 1999-357549	A2	19990720	<--	
	US 2000-180268P	P	20000204	<--	
	AU 2001-36685	A3	20010205	<--	
	US 2001-778154	A3	20010205	<--	
	US 2004-996945	A2	20041124		
	WO 2004-US39507	A	20041124		

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Tannins in method of isolating mucilaginous polysaccharides and uses for the polysaccharides thus obtained
AB The present invention provides a method of isolating mucilaginous polysaccharides from plants, cereals, cell cultures, or fungi such as mushrooms known to have mucilaginous or protein-bound polysaccharides with desirable biol. properties. The mucilaginous polysaccharides present in aqueous solution or tissue exts. are treated with tannins to form a complex which
is then separated from the solution The complex is then treated one or more times with either solvents or other substances in solution to remove the bounded tannins from the complex thereby and releasing the isolated polysaccharide. The polysaccharides prepared according to the present method retain properties that are substantially similar to those of the native polysaccharide as it is found in the resp. plant or cell. The polysaccharides thus prepared are used in a variety of products, e.g., in cosmetics, pharmaceuticals, and food products. This process is particularly suitable for isolating acetylated mannose polymers from aloe plants and beta glucans.
AN 2000:493312 HCAPLUS <<LOGINID::20080702>>
DN 133:101738
TI Tannins in method of isolating mucilaginous polysaccharides and uses for the polysaccharides thus obtained
IN Vittori, Natale
PA Vito-Mannan Polysaccharide L.L.C., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041541	A2	20000720	WO 2000-US759	20000111 <--
	WO 2000041541	A3	20011115		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2328092	A1	20000720	CA 2000-2328092	20000111 <--
	EP 1144456	A2	20011017	EP 2000-904309	20000111 <--
	EP 1144456	A3	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6482942	B1	20021119	US 2000-481111	20000111 <--
	MX 2000PA09966	A	20011211	MX 2000-PA9966	20001011 <--
PRAI	US 1999-115619P	P	19990112	<--	
	WO 2000-US759	W	20000111	<--	

L15 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Improved formulation for topical non-invasive application in vivo
AB A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided that

the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over is enabled. The formulation also contains 1 antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.

AN 2000:456858 HCAPLUS <<LOGINID::20080702>>

DN 133:94512

TI Improved formulation for topical non-invasive application in vivo

IN Cevc, Gregor

PA Idea Innovative Dermale Applikationen G.m.b.H., Germany

SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038653	A1	20000706	WO 1998-EP8421	19981223 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2356080	A1	20000706	CA 1998-2356080	19981223 <--
	AU 9925137	A	20000731	AU 1999-25137	19981223 <--
	AU 770803	B2	20040304		
	EP 1140021	A1	20011010	EP 1998-966846	19981223 <--
	EP 1140021	B1	20040804		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9816113	A	20011023	BR 1998-16113	19981223 <--
	HU 2001004424	A2	20020328	HU 2001-4424	19981223 <--
	HU 2001004424	A3	20021228		
	JP 2002533379	T	20021008	JP 2000-590607	19981223 <--
	EE 200100342	A	20021015	EE 2001-342	19981223 <--
	RU 2207844	C2	20030710	RU 2001-120008	19981223 <--
	AT 272391	T	20040815	AT 1998-966846	19981223 <--
	ES 2226203	T3	20050316	ES 1998-966846	19981223 <--
	PL 193824	B1	20070330	PL 1967-3494	19981223 <--
	HR 2001000309	A1	20020630	HR 2001-309	20010502 <--
	HR 2001000309	B1	20050630		
	NO 2001003164	A	20010822	NO 2001-3164	20010622 <--
	US 20020064524	A1	20020530	US 2001-887493	20010622 <--
	US 7175850	B2	20070213		
	MX 2001PA06424	A	20020604	MX 2001-PA6424	20010622 <--
	HK 1040629	A1	20050128	HK 2002-102230	20020323 <--
	US 20070184114	A1	20070809	US 2006-638091	20061212 <--
PRAI	WO 1998-EP8421	A	19981223	<--	
	US 2001-887493	A1	20010622	<--	

OS MARPAT 133:94512
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
AB The disclosed formulation is comprised of: (a) 0.1-5 weight dehydroepiandrosterone; (b) 0.5-3% acrylic gel, 1-3% guar gum, or 1-3% cellulose-derived gel; and optionally other ingredients such as hydrophilic gels, estradiol, vitamins, progesterone, minoxidil, hyaluronidase, vasoprotectants, plant exts., etc. The formulation has various pharmacol. applications, e.g. for treating menstrual disorders, mammary and gynecol. neoplasms, lipodystrophy, panniculopathy, circulatory disorders, bruises, muscular pain, obesity, diabetes, osteoporosis, aging, etc.
AN 1997:204223 HCAPLUS <<LOGINID::20080702>>
DN 126:190952
OREF 126:36787a,36790a
TI Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
IN Cabo Soler, Jose; Calderon Gomez, Jesus; Palacios Gil-Antunano, Santiago
PA Spain
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA Spanish
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703676	A1	19970206	WO 1996-ES153	19960719 <--
	W: AU, BR, CA, CN, JP, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ES 2098193	A1	19970416	ES 1995-1471	19950721 <--
	ES 2098193	B1	19971201		
	AU 9664196	A	19970218	AU 1996-64196	19960719 <--
PRAI	ES 1995-1471	A	19950721	<--	
	WO 1996-ES153	W	19960719	<--	

L15 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
AB Delivery to the colon of fatty acids, especially short-chain fatty acids (SCFA),
can be effected by covalently linking SCFA to a carrier, that is preferably a carbohydrate, by an ester link. The SCFA is protected by its link with the carbohydrate through the small intestine, and where the carbohydrate is digestible in the small intestine such as a digestible starch, the starch can also be protected from digestion in the small intestine by the substitution. Levels of SCFA such as acetate, propionate and butyrate may be elevated to have beneficial effects in the prevention of colonic disorders, such as rectal cancer, diverticulitis, colitis, diarrhea and constipation.
AN 1995:756390 HCAPLUS <<LOGINID::20080702>>
DN 123:142666
OREF 123:25401a,25404a
TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
IN Anisson, Geoffrey; Topping, David; Illman, Richard
PA Commonwealth Scientific and Industrial Research Organisation, Australia
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent

```
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9513801           A1    19950526    WO 1994-AU713          19941117 <--
         W:  AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
             GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LU, LV, MD, MG, MN,
             MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US,
             UZ, VN
         RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
             MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
             TD, TG
     CA 2176719            A1    19950526    CA 1994-2176719        19941117 <--
     CA 2176719            C     20070918
     AU 9481368            A     19950606    AU 1994-81368          19941117 <--
     AU 695906             B2    19980827
     EP 730447             A1    19960911    EP 1995-900575         19941117 <--
     EP 730447             B1    20020220
         R:  CH, DE, ES, FR, GB, IT, LI, NL, SE
     JP 09505060           T     19970520    JP 1994-514114         19941117 <--
     JP 4071823            B2    20080402    JP 1995-514114         19941117 <--
     US 5840860            A     19981124    US 1996-646294         19960905 <--
PRAI AU 1993-2454          A     19931117  <--
     WO 1994-AU713         W     19941117  <--


L15  ANSWER 16 OF 16  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Method for preparing diagnostic slide coated with immunoreactive
     substance-sensitized latex and water-soluble polymer
AB   The method comprises coating the slide with a reagent layer containing
     immunoreactive substance (e.g. antibody or antigen)-sensitized latex,
     water-soluble polymer (e.g. PVP), and optionally a water-soluble natural
compound
     (e.g. cyclodextrin), followed by natural drying to produce a stable and
     redissolvable coating.  Thus, monoclonal anti-mannan antibody was prepared,
     immobilized on latex, coated on a slide together with PVP, and used for
     detecting mannan derived from Candida tropicalis.
AN   1993:599163  HCAPLUS <<LOGINID::20080702>>
DN   119:199163
OREF 119:35405a,35408a
TI   Method for preparing diagnostic slide coated with immunoreactive
     substance-sensitized latex and water-soluble polymer
IN   Kondo, Kenji; Yoshimura, Makoto; Fujii, Masahiko
PA   Kureha Chemical Ind Co Ltd, Japan
SO   Jpn. Kokai Tokkyo Koho, 11 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   JP 05196623          A     19930806    JP 1992-171730         19920606 <--
     JP 2631796           B2    19970716
PRAI JP 1991-176213       A1    19910620  <--


=> file stnguide

COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 127.82     135.21
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                -34.40     -34.40

FILE 'STNGUIDE' ENTERED AT 15:32:07 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).



=> s guar or galactomannan

         11663 GUAR
          3183 GALACTOMANNAN
L1       13810 GUAR OR GALACTOMANNAN

=> s fluorouracil of fluorodeoxyuridine or fluoropyrimidine of cisplatin

         21389 FLUOROURACIL
          1919 FLUORODEOXYURIDINE
            74 FLUOROURACIL OF FLUORODEOXYURIDINE
               (FLUOROURACIL(1W)FLUORODEOXYURIDINE)
          1420 FLUOROPYRIMIDINE
         23605 CISPLATIN
             5 FLUOROPYRIMIDINE OF CISPLATIN
               (FLUOROPYRIMIDINE(1W)CISPLATIN)
L2           79 FLUOROURACIL OF FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CISPLA
               TIN

=> s leucovorin

L3         2637 LEUCOVORIN

=> s l1 and l2

L4            0 L1 AND L2

=> s l1 and l2 and l3

L5            0 L1 AND L2 AND L3

=> s l4 and (PY<2004 or AY<2004 or PRY<2004)

       23986121 PY<2004
        4778946 AY<2004
        4249769 PRY<2004
L6            0 L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l5 and (PY<2004 or AY<2004 or PRY<2004)

       23986121 PY<2004
        4778946 AY<2004
        4249769 PRY<2004
L7            0 L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
```

```
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                  2.69       3.11

FILE 'STNGUIDE' ENTERED AT 18:01:32 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.06       3.17

FILE 'HCAPLUS' ENTERED AT 18:02:04 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Jul 2008  VOL 149 ISS 1
FILE LAST UPDATED: 1 Jul 2008  (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s fluorouracil or fluorodeoxyuridine or fluoropyrimidine of cisplatin

         21389 FLUOROURACIL
          1919 FLUORODEOXYURIDINE
          1420 FLUOROPYRIMIDINE
         23605 CISPLATIN
             5 FLUOROPYRIMIDINE OF CISPLATIN
               (FLUOROPYRIMIDINE(1W)CISPLATIN)
L8       22775 FLUOROURACIL OR FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CISPLA
               TIN

=> s l1 and l8

L9          38 L1 AND L8

=> s l1 and l8 and l3

L10          6 L1 AND L8 AND L3
```

```
=> s l9 and (PY<2004 or AY<2004 or PRY<2004)

      23986121 PY<2004
       4778946 AY<2004
       4249769 PRY<2004
L11          18 L9 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l10 and (PY<2004 or AY<2004 or PRY<2004)

      23986121 PY<2004
       4778946 AY<2004
       4249769 PRY<2004
L12           2 L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 2.69       5.86

FILE 'STNGUIDE' ENTERED AT 18:02:11 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> d l11 1-18 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L11  ANSWER 1 OF 18  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Method for augmentation of intraepithelial and systemic exposure of
     therapeutic agents having substrate activity for cytochrome p450 enzymes
     and membrane efflux systems following vaginal and oral cavity
     administration
AB   The present invention relates to a method for augmentation of epithelial
     concentration and systemic exposure of therapeutic agents having a substrate
     affinity for cytochrome P 450 enzymes and membrane efflux transporter
     systems by using a vaginal or buccal drug delivery compns. and/or devices.
     Specifically, the invention relates to a method for augmentation of
     intraepithelial concentration and/or systemic bioavailability for delivery of
     anti-viral and/or anti-cancer therapeutic agents having a substrate
     affinity for cytochrome P 450 enzymes and membrane efflux systems by using
     a vaginal or buccal drug delivery of these drugs into the systemic
     circulation by delivering such drug to a subject in need thereof vaginally
     or buccally in an especially formulated composition increasing the drug's
     bioavailability by providing means for increasing the drug solubility and
     permeability through the vaginal or buccal mucosa.
AN   2007:175576  HCAPLUS <<LOGINID::20080702>>
DN   146:258964
TI   Method for augmentation of intraepithelial and systemic exposure of
     therapeutic agents having substrate activity for cytochrome p450 enzymes
     and membrane efflux systems following vaginal and oral cavity
     administration
IN   Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.
PA   USA
SO   U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209.
     CODEN: USXXCO
```

DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20070036834	A1	20070215	US 2006-522126	20060915	<--
	AU 765269	B2	20030911	AU 2001-54192	20010703	<--
	US 20030049302	A1	20030313	US 2002-226667	20020821	<--
	US 6982091	B2	20060103			
	US 20060002966	A1	20060105	US 2005-208209	20050818	<--
	AU 2006292507	A1	20070329	AU 2006-292507	20060915	
	CA 2622746	A1	20070329	CA 2006-2622746	20060915	
	WO 2007035515	A2	20070329	WO 2006-US36087	20060915	
	WO 2007035515	A3	20070927			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
PRAI	US 2001-315877P	P	20010829	<--		
	US 2002-226667	A1	20020821	<--		
	US 2005-208209	A2	20050818			
	US 2005-717680P	P	20050915			
	AU 1998-76976	A3	19980610	<--		
	WO 2006-US36087	W	20060915			

L11 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Nanoparticle compositions comprising antibodies for targeted delivery
AB The present invention is directed to compns. of one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof, and methods of using such compns. for targeting delivery of the one or more active agents to a desired site. The one or more active agents preferably have a particle size of ≤2 μ. The targeted delivery can be used, e.g., for disease diagnosis, imaging, or drug delivery. Thud, WIN-68209 particles wee stabilized by PEG-DSPE stabilizer.
AN 2005:472002 HCAPLUS <<LOGINID::20080702>>
DN 143:13359
TI Nanoparticle compositions comprising antibodies for targeted delivery
IN Liversidge, Elaine; Cunningham, James
PA Elan Pharma International Ltd., Ire.
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2005049091	A2	20050602	WO 2004-US37246	20041109	<--
	WO 2005049091	A3	20061109			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,					

```
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
            SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
            NE, SN, TD, TG
    US 20050147664       A1     20050707    US 2004-979792          20041103 <--
    CA 2545856           A1     20050602    CA 2004-2545856         20041109 <--
    EP 1689442           A2     20060816    EP 2004-810555          20041109 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
           HR, IS, YU
    JP 2007511513        T      20070510    JP 2006-539722          20041109 <--
PRAI US 2003-519251P     P      20031113  <--
    WO 2004-US37246      W      20041109

L11 ANSWER 3 OF 18  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI  Polysaccharide compositions and methods for hydrophobic drug delivery
AB  Disclosed herein are compns. and methods for the delivery and targeting of
    therapeutics using nanometer sized polysaccharide structures.  The methods
    and compns. described herein afford improved efficacy for pharmaceuticals
    such as antitumor drugs on metastatic tumor.  The methods described herein
    are applicable to all chemotherapeutic agents and are especially useful for
    poorly soluble (hydrophobic) drugs which when formulated with the present
    compns. render them deliverable in physiol. fluids.  The methods and
    compns. described herein also improve the efficacy of pharmaceutical
    agents by targeting carbohydrate receptors specific to tumors that mediate
    endocytosis or enhance delivery of the drug to the ultimate site of
    action.  For example, a paclitaxel-modified galactomannan (6
    mg/kg/60 mg/kg) complex was administered i.v. once a day for 5 days to
    mice implanted with human colon cancer.  While control untreated tumors
    grew well in all mice and reach about 600 mg in 30 days, the tumor in
    treated mice reach less than 200 mg in 30 days, a 200% reduction in tumor size
    vs. untreated control animals.
AN  2005:71073  HCAPLUS <<LOGINID::20080702>>
DN  142:162618
TI  Polysaccharide compositions and methods for hydrophobic drug delivery
IN  Platt, David; Zomer, Eliezer; Klyosov, Anatole
PA  Pro-Pharmaceuticals, Inc., USA
SO  PCT Int. Appl., 32 pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
    --------------      ----   --------    --------------------    --------
PI  WO 2005007110       A2     20050127    WO 2004-US22375         20040712 <--
    WO 2005007110       A9     20050728
    WO 2005007110       A3     20051006
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
           CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
           GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
           LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
           NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
           TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
           AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
           EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
           SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
           SN, TD, TG
```

```
     US 20050043272         A1    20050224    US 2004-889555          20040712 <--
     EP 1643969             A2    20060412    EP 2004-778075          20040712 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     CN 1838942             A     20060927    CN 2004-80024080        20040712 <--
     JP 2007531697          T     20071108    JP 2006-520260          20040712 <--
PRAI US 2003-486338P        P     20030711  <--
     WO 2004-US22375        W     20040712

L11  ANSWER 4 OF 18  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Medicinal oral preparations for colon delivery, medicinal oral
     preparations for treating colon cancer and medicinal oral preparations for
     treating colitis
AB   Disclosed is a medicinal oral preparation to be delivered to the large
     intestine comprising a core containing a pharmacol. active ingredient, an
     inner layer containing one or more cationic polymers and an outer layer
containing
     one or more anionic polymers whereby the core is coated, which is designed
     so that, in a disintegration test successively consisting of a vertical
     movement for 2 h in a first solution of pH 1.2, a vertical movement for 2 h
     in a second solution of pH 7.4 and a vertical movement in a third solution of
pH
     6.4, the average disintegration initiation point and the average disintegration
     completion point each falls within a period from 35 min to 130 min after
     starting the vertical movement in the third solution  Namely, disclosed is a
     medicinal oral preparation to be delivered to the large intestine, a medicinal
     oral preparation for treating colon cancer and a medicinal oral preparation for
     treating colitis which would not disintegrate in the stomach or small
     intestine but begin to disintegrate after attaining the large intestine
     and surely complete the disintegration while remaining in the large
     intestine.  A core composition containing 5-fluorouracil 25.6, lactose
     48.4, crystalline cellulose 20, low-substituted hydroxypropylcellulose (LH-21)
     5, and magnesium stearate 1 % was coated with an inner coating material
     containing Eudragit E 7, ethanol 70, water 19.5, and talc 3.5 %, and then with
     an outerlayer coating material containing Eudragit S 7, ethanol 70, water
     18.8, talc 3.5, and polyethylene glycol 6000 0.7 % to obtain a tablet for
     delivery to large intestine.
AN   2004:857365  HCAPLUS <<LOGINID::20080702>>
DN   141:337753
TI   Medicinal oral preparations for colon delivery, medicinal oral
     preparations for treating colon cancer and medicinal oral preparations for
     treating colitis
IN   Sato, Shuji; Goto, Takeshi; Tanida, Norifumi; Meno, Tatsuya; Yoshinaga,
     Takaaki; Yonemura, Keishi
PA   Hisamitsu Pharmaceutical Co., Inc., Japan
SO   PCT Int. Appl., 35 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2004087109       A1     20041014    WO 2003-JP3804          20030327 <--
        W:  CA, US
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IT, LU, MC, NL, PT, RO, SE, SI, SK, TR
     EP 1607087          A1     20051221    EP 2003-715485          20030327 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK
     US 20060188563      A1     20060824    US 2005-550586          20050922 <--
PRAI WO 2003-JP3804      W      20030327  <--
```

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preclinical studies of anticancer efficacy of 5-fluorouracil when co-administered with the 1,4-β-D- galactomannan
AB Soluble 1,4-β-D- galactomannan (GM) was obtained from a plant source by controlled acid hydrolysis and further purification under Good Manufacturing Practice (GMP) conditions. Co-administration of the GM along with 5-fluorouracil (5-FU) by i.v. injection to mice bearing human colon tumors (COLO 205 and HT-29) significantly increased efficacy of the 5-FU. This article describes the principal results of three sep. preclin. studies, employing (i) COLO 205-bearing mice at one dose of GM and 5-FU (ii) COLO 205-bearing mice at escalating GM doses in combination with 5-FU; and (iii) HT-29-bearing mice at two GM doses in combination with 5-FU with and without leucovorin. The studies have shown a GM dose-related effect with a maximum efficacy at 120 mg/kg/dose of GM. Effect of an addnl. oral administration of leucovorin was minimal. Combination of the GM with 5-FU, compared to 5-FU alone, resulted in the decrease in median tumor volume to 17%-65% and an increase in mean survival time (days) to 150%-190%, resp.
AN 2004:151188 HCAPLUS <<LOGINID::20080702>>
DN 141:184724
TI Preclinical studies of anticancer efficacy of 5-fluorouracil when co-administered with the 1,4-β-D- galactomannan
AU Klyosov, Anatole A.; Platt, David; Zomer, Eliezer
CS Pro-Pharmaceuticals, Newton, MA, USA
SO Preclinica (2003), 1(4), 175-183, 186
CODEN: PRECC8; ISSN: 1542-9431
PB Eaton Publishing
DT Journal
LA English
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Medical goods comprising heparin or chitosan-based hemocompatible coating
AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.
AN 2003:913055 HCAPLUS <<LOGINID::20080702>>
DN 139:399770
TI Medical goods comprising heparin or chitosan-based hemocompatible coating
IN Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato

PA Hemoteq G.m.b.H., Germany
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003094990	A1	20031120	WO 2003-DE1253	20030415	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	DE 10221055	A1	20031127	DE 2002-10221055	20020510	<--
	DE 10221055	B4	20071025			
	DE 10261986	A1	20040318	DE 2002-10261986	20020510	<--
	DE 10261986	B4	20080131			
	AU 2003240391	A1	20031111	AU 2003-240391	20030415	<--
	AU 2003240391	B2	20070517			
	CA 2484269	A1	20031120	CA 2003-2484269	20030415	<--
	CN 1543362	A	20041103	CN 2003-800770	20030415	<--
	EP 1501565	A1	20050202	EP 2003-729829	20030415	<--
	EP 1501565	B1	20061102			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
	BR 2003011446	A	20050315	BR 2003-11446	20030415	<--
	CN 1665554	A	20050907	CN 2003-815926	20030415	<--
	JP 2005534724	T	20051117	JP 2004-503070	20030415	<--
	AT 344064	T	20061115	AT 2003-729829	20030415	<--
	ES 2276065	T3	20070616	ES 2003-729829	20030415	<--
	NZ 536331	A	20070831	NZ 2003-536331	20030415	<--
	IN 2004MN00606	A	20050218	IN 2004-MN606	20041028	<--
	ZA 2004008791	A	20050527	ZA 2004-8791	20041028	<--
	ZA 2004008757	A	20050531	ZA 2004-8757	20041028	<--
	US 20050176678	A1	20050811	US 2004-513982	20041108	<--
	MX 2004PA11112	A	20050714	MX 2004-PA11112	20041109	<--
	IN 2005MN01451	A	20070706	IN 2005-MN1451	20051230	<--
PRAI	US 2002-378676P	P	20020509	<--		
	DE 2002-10221055	A	20020510	<--		
	WO 2003-DE1253	W	20030415	<--		
	IN 2004-MN606	A3	20041028			

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Multiplex drug delivery system suitable for oral administration
AB A multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissoln. profiles for an active agent when compared to one another and when compared to that of the entire multiplex drug delivery unit, and substantially enveloped by a scored film coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages can provide a convenient and cost effective drug delivery unit, particularly for patients with a regimen of prescribed dosages that varies during their treatment period. Formulation of an isosorbide-5-mononitrate

tablet containing immediate-release and extended-release layers is disclosed.
AN 2003:603864 HCAPLUS <<LOGINID::20080702>>
DN 139:154899
TI Multiplex drug delivery system suitable for oral administration
IN Ting, Richard; Hsiao, Charles
PA Impax Pharmaceuticals Inc., USA
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6602521	B1	20030805	US 1998-164642	19980929 <--
	WO 2000018447	A2	20000406	WO 1999-US20807	19990913 <--
	WO 2000018447	A3	20040219		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1416920	A2	20040512	EP 1999-948182	19990913 <--
	EP 1416920	B1	20070110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	ES 2278455	T3	20070801	ES 1999-948182	19990913 <--
	TW 228997	B	20050311	TW 1999-88115834	19990914 <--
	US 20030203028	A1	20031030	US 2003-435013	20030512 <--
PRAI	US 1998-164642	A	19980929	<--	
	WO 1999-US20807	W	19990913	<--	

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets
AB The objective of the present study is to compare the guar gum-based colon-targeted tablets of 5-fluorouracil against an immediate release tablet by in vitro dissoln. and in vivo pharmacokinetic studies in human volunteers. Twelve healthy volunteers participated in the study. 5-Fluorouracil was administered at a dose of 50 mg both in immediate release tablet and colon-targeted tablet. On oral administration of colon-targeted tablets, 5-fluorouracil started appearing in the plasma at 6 h, and reached the peak concentration (Cmax of 216±15 ng/mL) at 7.6±0.1 h (Tmax), whereas the immediate release tablets produced peak plasma concentration (Cmax of 278±21 ng/mL) at 0.6±0.01 h (Tmax). The AUC0-∞ for 5- fluorouracil from colon-targeted tablet and immediate release tablet were found to be 617±39 and 205±21 ng/mL/h, resp. Colon-targeted tablets showed delayed tmax, delayed absorption time (ta), decreased Cmax and decreased absorption rate constant when compared to the immediate release tablets. The results of the study indicated that the guar gum-based colon-targeted formulation did not release the drug in stomach and small intestine, but delivered it to the colon resulting in a slow absorption of the drug and making it available for local action in colon.
AN 2003:598184 HCAPLUS <<LOGINID::20080702>>
DN 140:204939

TI In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets
AU Krishnaiah, Y. S. R.; Satyanarayana, V.; Dinesh Kumar, B.; Karthikeyan, R. S.; Bhaskar, P.
CS Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530 003, India
SO European Journal of Pharmaceutical Sciences (2003), 19(5), 355-362
CODEN: EPSCED; ISSN: 0928-0987
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Oral pharmaceutical formulations for colon delivery, colon cancer treatment, and colitis treatment
AB The oral pharmaceutical formulations for colon delivery have coating layers including an inner layer containing ≥1 cationic polymer and an outer layer containing ≥1 anionic polymer. In disintegration test involving up-and-down movements in a 1st solution (pH 1.2) for 2 h, up-and-down movements in a 2nd solution (pH 7.4) for 2 h, and up-and-down movements in a 3rd solution (pH 6.4), both of the average disintegration initiation time and average disintegration termination time of the pharmaceutical formulations are within 35-130 min after initiation of up-and-down movements in the 3rd solution Core tablets containing Sm2O3 5.13, lactose 68.62, crystalline cellulose 20.00, low-substituted hydroxypropyl cellulose 5.03, citric acid 0.26, and Mg stearate 0.97 weight part were spray-coated with a composition containing Eudragit E (Me methacrylate-Bu methacrylate-dimethylaminoethyl methacrylate copolymer) 7, EtOH 70, H2O 19.5, and talc 3.5 weight parts and then with a composition containing Eudragit S
(methacrylic acid-Me methacrylate copolymer) 7.0, EtOH 70.0, H2O 18.8, talc 3.5, and polyethylene glycol 0.7 weight part to give coated placebo tablets showing average disintegration initiation time and average disintegration
termination time in the 3rd solution (pH 6.4) of 47 and 61 min, resp. It was observed by gamma scintigraphy that 100% of the Sm-containing coated tablets were
delivered to the colon when orally administered to humans.
AN 2003:550199 HCAPLUS <<LOGINID::20080702>>
DN 139:106464
TI Oral pharmaceutical formulations for colon delivery, colon cancer treatment, and colitis treatment
IN Sato, Shuji; Goto, Takeshi; Tanida, Nobufumi; Meno, Tatsuya; Yoshinaga, Takaaki; Yonemura, Keiji
PA Hisamitsu Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003201256	A	20030718	JP 2001-399310	20011228 <--
PRAI JP 2001-399310		20011228 <--		

L11 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Malleable protein matrix and uses thereof
AB The present invention relates to a malleable protein matrix (MPM) which is

the reaction product of the agglomeration of proteins after a fermentation process, exhibits biol. activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophilic substances. The present invention also relates to the process for the preparation of the malleable protein matrix and its uses in food, drug, medical and cosmetic products.

AN 2003:511049 HCAPLUS <<LOGINID::20080702>>
DN 139:84363
TI Malleable protein matrix and uses thereof
IN Simard, Eric; Pilote, Dominique; Dupont, Claude; Lajoie, Nathalie; Paquet, Marcel; Lemieux, Pierre; Goyette, Philippe
PA Technologies Biolactis Inc., Can.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053158	A2	20030703	WO 2002-CA1988	20021220 <--
	WO 2003053158	A3	20030828		
	WO 2003053158	A9	20040408		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2470776	A1	20030703	CA 2002-2470776	20021220 <--
	AU 2002351606	A1	20030709	AU 2002-351606	20021220 <--
	EP 1458247	A2	20040922	EP 2002-787279	20021220 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005513076	T	20050512	JP 2003-553926	20021220 <--
	US 20060057131	A1	20060316	US 2005-499313	20050224 <--
PRAI	US 2001-341232P	P	20011220	<--	
	WO 2002-CA1988	W	20021220	<--	

L11 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
AB Methods and compns. for treating cancer with a formulation are provided in which a polysaccharide, galactomannan, is co-administered with a therapeutic agent to a subject to reduce toxicity and/or enhance efficacy of the agent for the subject. Co-administration of galactomannan (120 mg/kg/dose) and 5-FU (75 mg/kg/dose) on a q4d+3 schedule brought a remarkable effect in NCr-nu athymic nude mice s.c. implanted with COLO 205 human colon tumors. It caused a significant delay in quadrupling of tumor weight, from 12.5 days for untreated animals (control) and 23.7 and 15.5 days for 5-FU alone and galactomannan alone, resp., to 56.0 days for their combination. Mean survival time shifted from 14.2 days (control, untreated animals) and 23.7 days (5-FU treatment) to 44.2 days for a combination treatment. Galactomannan was isolated and purified from seeds of Gleditsia triacanthos.
AN 2003:261019 HCAPLUS <<LOGINID::20080702>>
DN 138:281098
TI Co-administration of a polysaccharide with a chemotherapeutic agent for

the treatment of cancer
IN Klyosov, Anatole; Platt, David
PA Pro-Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 818,596.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20030064957	A1	20030403	US 2002-108237	20020327	<--
	US 7012068	B2	20060314			
	US 6645946	B1	20031111	US 2001-818596	20010327	<--
	US 20040038935	A1	20040226	US 2003-649130	20030827	<--
	US 6914055	B2	20050705			
	US 20040038916	A1	20040226	US 2003-649131	20030827	<--
	US 6982255	B2	20060103			
	WO 2005020900	A2	20050310	WO 2004-US27291	20040823	<--
	WO 2005020900	A3	20050915			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	WO 2005020901	A2	20050310	WO 2004-US27292	20040824	<--
	WO 2005020901	A3	20050526			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
PRAI	US 2001-818596	A2	20010327	<--		
	US 2001-317092P	P	20010904	<--		
	US 2003-649130	A	20030827	<--		
	US 2003-649131	A	20030827	<--		

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
AB Methods and compns. for treating cancer with a formulation are provided in which a polysaccharide, galactomannan is coadministered with a chemotherapeutic agent to a subject to reduce toxicity and/or to enhance efficacy of the agent for the subject.
AN 2002:754226 HCAPLUS <<LOGINID::20080702>>
DN 137:257637
TI Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer

IN Klyosov, Anatole; Platt, David
PA Pro-Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076474	A1	20021003	WO 2002-US9524	20020327 <--
	W: JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	US 6645946	B1	20031111	US 2001-818596	20010327 <--
	EP 1383516	A1	20040128	EP 2002-731178	20020327 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2004525143	T	20040819	JP 2002-574987	20020327 <--
	US 20040038935	A1	20040226	US 2003-649130	20030827 <--
	US 6914055	B2	20050705		
	US 20040038916	A1	20040226	US 2003-649131	20030827 <--
	US 6982255	B2	20060103		
	WO 2005020900	A2	20050310	WO 2004-US27291	20040823 <--
	WO 2005020900	A3	20050915		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005020901	A2	20050310	WO 2004-US27292	20040824 <--
	WO 2005020901	A3	20050526		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-818596	A	20010327 <--		
	US 2001-317092P	P	20010904 <--		
	WO 2002-US9524	W	20020327 <--		
	US 2003-649130	A	20030827 <--		
	US 2003-649131	A	20030827 <--		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil
AB I.v. administration of 5-fluorouracil for colon cancer therapy produces severe systemic side-effects due to its cytotoxic effect on

normal cells. The broad objective of the present study was to develop novel tablet formulations for site-specific delivery of 5-fluorouracil to the colon without the drug being released in the stomach or small intestine using guar gum as a carrier. Fast-disintegrating 5-fluorouracil core tablets were compression coated with 60% (FHV-60), 70% (FHV-70) and 80% (FHV-80) of guar gum, and were subjected to in vitro drug release studies. The amount of 5-fluorouracil released from the compression-coated tablets in the dissoln. medium at different time intervals was estimated by a HPLC method. Guar gum compression-coated tablets released only 2.5-4% of the 5-fluorouracil in simulated GI fluids. When the dissoln. study was continued in simulated colonic fluids (4% w/v rat cecal content medium) the compression-coated FHV-60, FHV-70 and FHV-80 tablets released another 70, 55 and 41% of the 5-fluorouracil resp. The results of the study show that compression-coated tablets containing 80% (FHV-80) of guar gum are most likely to provide targeting of 5-fluorouracil for local action in the colon, since they released only 2.38% of the drug in the physiol. environment of the stomach and small intestine. The FHV-80 formulation showed no change either in phys. appearance, drug content or dissoln. pattern after storage at 40°/RH 75% for 6 mo. The differential scanning calorimetric study showed that 5-fluorouracil did not interact with the formulation excipients used in the study.

AN 2002:546865 HCAPLUS <<LOGINID::20080702>>
DN 138:260264
TI In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil
AU Krishnaiah, Y. S. R.; Satyanarayana, V.; Dinesh Kumar, B.; Karthikeyan, R. S.
CS College of Engineering, Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530 003, India
SO European Journal of Pharmaceutical Sciences (2002), 16(3), 185-192
CODEN: EPSCED; ISSN: 0928-0987
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of aqueous clear solution dosage forms with bile acids
AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

AN 2002:185616 HCAPLUS <<LOGINID::20080702>>

DN 136:252482
TI Preparation of aqueous clear solution dosage forms with bile acids
IN Yoo, Seo Hong
PA USA
SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020031558	A1	20020314	US 2001-778154	20010205 <--
	US 7303768	B2	20071204		
	US 6251428	B1	20010626	US 1999-357549	19990720 <--
	US 20030186933	A1	20031002	US 2002-309603	20021204 <--
	US 7166299	B2	20070123		
	US 20050158408	A1	20050721	US 2004-996945	20041124 <--
	AU 2004325203	A1	20060601	AU 2004-325203	20041124
	CA 2588168	A1	20060601	CA 2004-2588168	20041124
	EP 1819318	A1	20070822	EP 2004-812094	20041124
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101065110	A	20071031	CN 2004-80044467	20041124
	BR 2004019213	A	20071218	BR 2004-19213	20041124
	JP 2008521800	T	20080626	JP 2007-543006	20041124
	AU 2006203315	A1	20060824	AU 2006-203315	20060803 <--
	US 20070072828	A1	20070329	US 2006-522162	20060915 <--
	IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
	KR 2007098821	A	20071005	KR 2007-714361	20070622
	US 20080057133	A1	20080306	US 2007-934505	20071102 <--
PRAI	US 1998-94069P	P	19980724	<--	
	US 1999-357549	A2	19990720	<--	
	US 2000-180268P	P	20000204	<--	
	AU 2001-36685	A3	20010205	<--	
	US 2001-778154	A3	20010205	<--	
	US 2004-996945	A2	20041124		
	WO 2004-US39507	A	20041124		

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
AB A colonic drug delivery composition contains a first polysaccharide and a second polysaccharide wherein both polysaccharides are degradable by colonic enzymes and are mixed at a environmental pH of about 7 or above. A colon selective pharmaceutical composition and dosage form for oral delivery of a drug, nutrient, diagnostic reagent, or mixture thereof includes the drug, nutrient, diagnostic reagent, or mixture thereof in contact with the polysaccharide composition A method of preparing such a colonic drug delivery composition and the colon selective pharmaceutical composition and dosage form are also disclosed. Capsules filled with budesonide pellets were coated with a composition containing pectin and guar gum at the ratio of 4 to 1 (pH 8), to a thickness of 15 mg/cm2. The capsules were disintegrated in 60 min in simulated colonic fluid, but not disintegrated in simulated gastric or intestinal fluid during 24 h studies.
AN 2000:68148 HCAPLUS <<LOGINID::20080702>>
DN 132:113102
TI Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides

IN Lee, Seung Seo; Lim, Chang Baeg; Pai, Chaul Min; Lee, Sujung; Park, In; Seo, Moon Gun; Park, Heenam
PA Samyang Corporation, S. Korea
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 974344	A2	20000126	EP 1999-305600	19990715 <--
	EP 974344	A3	20000301		
	EP 974344	B1	20040303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	KR 2000011247	A	20000225	KR 1999-14665	19990423 <--
	CA 2336815	A1	20000203	CA 1999-2336815	19990520 <--
	CA 2336815	C	20050607		
	WO 2000004924	A1	20000203	WO 1999-KR250	19990520 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9940627	A	20000214	AU 1999-40627	19990520 <--
	AU 744183	B2	20020214		
	JP 2002521346	T	20020716	JP 2000-560917	19990520 <--
	JP 4088420	B2	20080521		
	US 6413494	B1	20020702	US 1999-318579	19990525 <--
	AT 260649	T	20040315	AT 1999-305600	19990715 <--
	ES 2214813	T3	20040916	ES 1999-305600	19990715 <--
	KR 2001074641	A	20010804	KR 2001-700082	20010104 <--
	MX 2001PA00768	A	20020408	MX 2001-PA768	20010122 <--
PRAI	KR 1998-29740	A	19980723 <--		
	KR 1999-14665	A	19990423 <--		
	WO 1999-KR250	W	19990520 <--		

L11 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Polymer-based press-coated, pulsatile drug delivery system suitable for oral administration
AB A press coated, pulsatile drug delivery system suitable for oral administration having an immediate-release compartment, which contains a compressed blend of an active agent and one or more polymers, substantially enveloped by an extended-release compartment, which contains a compressed blend of the active agent and hydrophilic and hydrophobic polymers, can provide a substantially first order delivery of the active agent, interrupted by a timed, pulsed delivery of an increased amount of the active agent; and when the extended-release compartment is substantially enveloped by an optional instant-release compartment, can provide a dose sufficient to exceed the liver's metabolic capacity and to maintain therapeutic levels, preferably throughout a 24-h period. E.g, extended-release tablets of isosorbide 5-mononitrate (ISMN) were prepared The immediate-release compartment contained ISMN mixed with silica and then blended first with microcryst. cellulose and then with croscarmellose sodium and Mg stearate; the powder blend was compressed to obtain a core tablet. The core tablets were then press-coated with a blend containing ISMN, silica, hydroxypropyl Me cellulose, microcryst. cellulose, hydrogenated vegetable oil and Mg stearate. The hardness of the tablets was maintained at 12 ± 4 kp.

AN 1999:659216 HCAPLUS <<LOGINID::20080702>>
DN 131:291287
TI Polymer-based press-coated, pulsatile drug delivery system suitable for oral administration
IN Ting, Richard; Hsiao, Charles
PA Impax Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9951209	A1	19991014	WO 1999-US6987	19990331 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6372254	B1	20020416	US 1998-53491	19980402 <--
	AU 9932182	A	19991025	AU 1999-32182	19990331 <--
	TW 245646	B	20051221	TW 1999-88105321	19990402 <--
PRAI	US 1998-53491	A	19980402	<--	
	WO 1999-US6987	W	19990331	<--	

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence
AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO4, Fe, Mg trisilicate, and a bioadhesive polymer, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated containing nifedipine with micronized crosslinked PVP (1:5) 240, BaSO4 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.
AN 1993:154582 HCAPLUS <<LOGINID::20080702>>
DN 118:154582
OREF 118:26399a,26402a
TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence
IN Esposito, Pierandrea; Carli, Fabio
PA Vectorpharma International S.p.A., Italy
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526862	A1	19930210	EP 1992-113187	19920803 <--
	EP 526862	B1	19960214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 134134	T	19960215	AT 1992-113187	19920803 <--
	ES 2086029	T3	19960616	ES 1992-113187	19920803 <--
PRAI	IT 1991-MI2212	A	19910806	<--	

```
L11  ANSWER 18 OF 18  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Antitumor activity of xanthan gum
AB   Xanthan gum  [11138-66-2] was the most effective antitumor agent among 11
     food additives tested in mice implanted with Ehrlich ascites tumor;
     xanthan gum was effective when given i.p. before or after tumor
     implantations.  In S-180 tumor-bearing mice, a synergistic effect was
     observed between xanthan gum and 5-fluorouracil  [51-21-8] or
     bleomycin  [11056-06-7], but no synergism was noted when xanthan gum was
     combined with cyclophosphamide  [50-18-0].
AN   1987:131313  HCAPLUS <<LOGINID::20080702>>
DN   106:131313
OREF 106:21255a,21258a
TI   Antitumor activity of xanthan gum
AU   Oda, Munehiro
CS   Meiji Inst. Health Sci., Japan
SO   Yakuri to Chiryo (1973-2000) (1985), 13(10), 5743-50
     CODEN: YACHDS; ISSN: 0386-3603
DT   Journal
LA   Japanese


=> d his

     (FILE 'HOME' ENTERED AT 18:00:00 ON 02 JUL 2008)

     FILE 'HCAPLUS' ENTERED AT 18:01:21 ON 02 JUL 2008
L1        13810 S GUAR OR GALACTOMANNAN
L2           79 S FLUOROURACIL OF FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L3         2637 S LEUCOVORIN
L4            0 S L1 AND L2
L5            0 S L1 AND L2 AND L3
L6            0 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)
L7            0 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 18:01:32 ON 02 JUL 2008

     FILE 'HCAPLUS' ENTERED AT 18:02:04 ON 02 JUL 2008
L8        22775 S FLUOROURACIL OR FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L9           38 S L1 AND L8
L10           6 S L1 AND L8 AND L3
L11          18 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12           2 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 18:02:11 ON 02 JUL 2008

     FILE 'HCAPLUS' ENTERED AT 18:02:19 ON 02 JUL 2008

     FILE 'STNGUIDE' ENTERED AT 18:02:21 ON 02 JUL 2008

=> log hold

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.06      61.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -14.40

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:02:23 ON 02 JUL 2008
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 18:08:11 ON 02 JUL 2008
FILE 'STNGUIDE' ENTERED AT 18:08:11 ON 02 JUL 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	61.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-14.40

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	61.17
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-14.40

FILE 'HCAPLUS' ENTERED AT 18:09:45 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 2 Jul 2008 VOL 149 ISS 1
FILE LAST UPDATED: 1 Jul 2008 (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s interferon or interleukin

```
         83968 INTERFERON
        179098 INTERLEUKIN
L13     235409 INTERFERON OR INTERLEUKIN

=> s l1 and l13

L14         38 L1 AND L13

=> s l1 and l3 and l13

L15          3 L1 AND L3 AND L13

=> s l14 and (PY<2004 or AY<2004 or PRY<2004)

       23986121 PY<2004
        4778946 AY<2004
        4249769 PRY<2004
L16          23 L14 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l15 and (PY<2004 or AY<2004 or PRY<2004)

       23986121 PY<2004
        4778946 AY<2004
        4249769 PRY<2004
L17           1 L15 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 2.69      63.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -14.40

FILE 'STNGUIDE' ENTERED AT 18:09:53 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> d l16 1-23 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L16  ANSWER 1 OF 23  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Nonsteroidal immunomodulating kit and composition and uses thereof
AB   A composition and therapeutic kit including an aerosol packaging assembly
     including a container accommodating a pressurized product and an outlet
     capable of releasing a foamable composition, including a nonsteroidal
     immunomodulating agent as a foam.  The pressurized product includes a
     foamable composition including: a) a container accommodating a pressurized
     product; and b) an outlet capable of releasing the pressurized product as
     a foam; wherein the pressurized product comprises a foamable composition
     including: i. a nonsteroidal immunomodulating agent; ii. at least one organic
     carrier selected from the group consisting of a hydrophobic organic carrier,
```

a polar solvent, an emollient and mixts. thereof, at a concentration of about 2%
to about 50% by weight; iii. a surface-active agent; iv. about 0.1% to about 5% by weight of a therapeutically active foam adjuvant, selected from the group consisting of a fatty alc., a fatty acid, a hydroxy fatty acid; and mixts. thereof; v. about 0.01 % to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; vi. water; and vii. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition

AN 2005:1132617 HCAPLUS <<LOGINID::20080702>>
DN 143:393082
TI Nonsteroidal immunomodulating kit and composition and uses thereof
IN Tamarkin, Dov; Eini, Meir; Friedman, Doron
PA Foamix Ltd., Israel
SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 911,367.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050232869	A1	20051020	US 2005-78902	20050311 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050069566	A1	20050331	US 2004-911367	20040804 <--
	ZA 2005003298	A	20060830	ZA 2005-3298	20050425 <--
	WO 2007007208	A2	20070118	WO 2006-IB2755	20060310
	WO 2007007208	A3	20070830		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1863447	A2	20071212	EP 2006-808940	20060310
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	AU 2006201878	A1	20070927	AU 2006-201878	20060504 <--
	US 20070253911	A1	20071101	US 2007-717897	20070313 <--
	US 20070292359	A1	20071220	US 2007-811140	20070607 <--
	US 20080044444	A1	20080221	US 2007-825406	20070705 <--
PRAI	IL 2002-152486	A	20021025	<--	
	US 2002-429546P	P	20021129	<--	

US	2003-492385P	P	20030804	<--
WO	2003-IB5527	A2	20031024	<--
US	2004-911367	A2	20040804	
US	2003-497648P	P	20030825	<--
US	2003-530015P	P	20031216	<--
US	2004-835505	A2	20040428	
US	2004-922358	A2	20040820	
US	2005-78902	A	20050311	
US	2005-124676	A2	20050509	
US	2005-696878P	P	20050706	
US	2005-700702P	P	20050719	
US	2005-532618	A2	20051222	
WO	2006-IB2755	W	20060310	
US	2006-781868P	P	20060313	
US	2006-811627P	P	20060607	
US	2006-818634P	P	20060705	
US	2006-481596	A2	20060706	
US	2006-488989	A2	20060719	
US	2007-653205	A2	20070112	
US	2007-897638P	P	20070126	
US	2007-899176P	P	20070202	
US	2007-717897	A2	20070313	

L16 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Compositions and methods for treating burns
AB The present invention provides compns. and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof; and a pharmaceutically acceptable excipient. For example, for example, a topical composition HR341g was prepared by mixing dicalcium phosphate dihydrate 1150 g, insol. sodium metaphosphate 700 g, sorbitol syrup (70% solution) 1250 g, guar gum 225 g, xanthan gum 90 g, monosodium phosphate 15 g, sodium monofluorophosphate 477 g, aminopterin 80 g, titanium dioxide 30 g, sodium dodecylbenzene sulfate 25 g, water 1200 g, trimagnesium phosphate 40 g, and hydroxethyl cellulose 157.5. A patient suffering from 2nd and 3rd degree burns was treated with HR341g applied to the burn areas. Edema was substantially reduced at the burn site. There was some inflammation, which was necessary for proper healing, but there were no excessive reactions. The patient suffered min. associated disease responses, because the environment a burn wound needed for microorganisms to proliferate was altered with HR431g.
AN 2005:324001 HCAPLUS <<LOGINID::20080702>>
DN 142:379383
TI Compositions and methods for treating burns
IN Hicks, Terry; Kohutka, Jeffrey
PA Kohi Corporation, USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005032470	A2	20050414	WO 2004-US31917	20040930 <--
WO 2005032470	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

```
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    AU 2004277977          A1    20050414    AU 2004-277977          20040930 <--
    CA 2540742             A1    20050414    CA 2004-2540742         20040930 <--
    EP 1667648             A2    20060614    EP 2004-789212          20040930 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
    CN 1886128             A     20061227    CN 2004-80035410        20040930 <--
    JP 2007507512          T     20070329    JP 2006-534052          20040930 <--
    US 20050281820         A1    20051222    US 2004-12210           20041216 <--
    MX 2006PA03573         A     20060831    MX 2006-PA3573          20060330 <--
    IN 2006CN01090         A     20070817    IN 2006-CN1090          20060330 <--
PRAI US 2003-506745P       P     20030930  <--
    WO 2004-US31917        W     20040930

L16  ANSWER 3 OF 23  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Co-administration of a polysaccharide with a chemotherapeutic agent for
     the treatment of cancer
AB   Disclosed herein are compns. and methods for treating diseases such as
     cancer.  The compns. comprise polysaccharides in an admixt. with one or
     more therapeutic agents.  This admixt. can be administered to a subject in
     need thereof using any known method of administration.  The therapeutic
     agent, if administered alone, can cause undesirable side-effects in the
     subject.  The polysaccharide component (e.g., galactomannan)
     minimizes or eliminates these side effects.  The compns. described herein
     effectuate an enhanced therapeutic effect along with reduced toxicity.
     5-FU and galactomannan worked synergistically.
AN   2005:219721  HCAPLUS <<LOGINID::20080702>>
DN   142:285217
TI   Co-administration of a polysaccharide with a chemotherapeutic agent for
     the treatment of cancer
IN   Zomer, Eliezer; Platt, David
PA   USA
SO   U.S. Pat. Appl. Publ., 30 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 20050053664      A1     20050310    US 2003-657508          20030908 <--
     AU 2004272022       A1     20050324    AU 2004-272022          20040907 <--
     WO 2005025501       A2     20050324    WO 2004-US28883         20040907 <--
     WO 2005025501       A3     20050519
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    EP 1662874           A2     20060607    EP 2004-783211          20040907 <--
```

	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004013410	A	20061010	BR 2004-13410	20040907 <--
	CN 1867252	A	20061122	CN 2004-80030017	20040907 <--
	JP 2007505041	T	20070308	JP 2006-525488	20040907 <--
PRAI	US 2003-657508	A	20030908	<--	
	WO 2004-US28883	W	20040907		

L16 ANSWER 4 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Dissolvable backing layer for use with a transmucosal delivery device

AB A water-dissolvable drug delivery device is designed so as to reliably maintain a drug or active agent within a defined region against a mucosal surface. The drug delivery device comprises a water-dissolvable backing layer, an adhesive layer adjacent to at least a portion of the backing layer, and an active layer that is circumscribed by the backing layer and adhesive layer. The backing layer may optionally include a water-dissolvable hydrophilic region and a non-hydrophilic region at least partially encapsulated within the hydrophilic region that inhibits migration of water, drugs, or other active agents through the backing layer. The adhesive layer may be water-activated or it may have a peelable cover layer that, when removed, exposes the adhesive material. The active layer may comprise any drug or other active agent, either alone or in combination with (i) an enhancer that increases the ability of the drug or other active agent to diffuse through a mucosal membrane and/or (ii) a matrix material such as an alginate to hold the active layer together. A patch contained an active layer comprising Na alginate interferon α2b, Na taurocholate, and water; an adhesive layer comprising PEG, polyacrylic acid, and water; and a backing layer comprising gelatin, glycerin, dodecyltrimethylammonium bromide, and water.

AN 2004:964611 HCAPLUS <<LOGINID::20080702>>

DN 141:400935

TI Dissolvable backing layer for use with a transmucosal delivery device

IN Zhang, Hao

PA Cephalon, Inc., USA

SO U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040224007	A1	20041111	US 2004-841892	20040507 <--
	US 7276246	B2	20071002		
	CA 2523787	A1	20041202	CA 2004-2523787	20040510 <--
	WO 2004103341	A2	20041202	WO 2004-US14555	20040510 <--
	WO 2004103341	A3	20050421		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1626704	A2	20060222	EP 2004-751781	20040510 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006528975	T	20061228	JP 2006-532913	20040510 <--

```
     MX 2005PA12010        A      20060831    MX 2005-PA12010         20051108 <--
PRAI US 2003-469497P       P      20030509  <--
     US 2004-841892        A      20040507
     WO 2004-US14555       W      20040510
RE.CNT  107   THERE ARE 107 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 5 OF 23  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Use of compounds for the prevention of drug-induced cell toxicity
AB   The present invention relates to the use of compds. for the manufacture of a
     medicament for the prophylaxis and/or treatment of induced cell toxicity,
     such as nephrotoxicity and ototoxicity, in particular where the cell
     toxicity is induced by a medical treatment.  In a preferred embodiment the
     compds. have at least two nitrogen atoms, more preferably at least two
     amino groups.  The compds. according to the invention are capable of
     blocking binding of cell toxic compds. to the megalin receptor, and
     thereby inhibiting uptake of the cell toxic compds. into cells.  The
     invention further relates to novel compds. for use in said treatment, as
     well as a method for reducing the cell toxicity of cell toxic compds.
AN   2004:817689  HCAPLUS <<LOGINID::20080702>>
DN   141:325783
TI   Use of compounds for the prevention of drug-induced cell toxicity
IN   Nykjaer, Anders
PA   Arhus Universitet, Den.; Recepticon Aps
SO   PCT Int. Appl., 55 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2004084876       A2     20041007    WO 2004-DK205           20040325 <--
     WO 2004084876       A3     20041223
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW:  BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     AU 2004224788        A1     20041007    AU 2004-224788          20040325 <--
     CA 2560522           A1     20041007    CA 2004-2560522         20040325 <--
     EP 1610773           A2     20060104    EP 2004-723168          20040325 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
     BR 2004008699        A      20060328    BR 2004-8699            20040325 <--
     CN 1794982           A      20060628    CN 2004-80014657        20040325 <--
     JP 2006520761        T      20060914    JP 2006-504337          20040325 <--
     MX 2005PA10143       A      20060317    MX 2005-PA10143         20050922 <--
     US 20070004727       A1     20070104    US 2005-550488          20050926 <--
     IN 2005CN02770       A      20070525    IN 2005-CN2770          20051026 <--
PRAI DK 2003-459          A      20030326  <--
     WO 2004-DK205        W      20040325

L16  ANSWER 6 OF 23  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Autologous ghrelin and encoding nucleic acid and foreign T cell epitope
     conjugates for vaccination against obesity and excess body fat increase or
```

loss in human and animal

AB Disclosed are novel methods that generally rely on immunization against autologous ghrelin. Immunization is preferably effected by administration of analogs of autologous ghrelin, said analogs being capable of inducing antibody production against the autologous ghrelin polypeptides. Especially preferred as an immunogen is autologous ghrelin, which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against ghrelin and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

AN 2004:252369 HCAPLUS <<LOGINID::20080702>>

DN 140:269531

TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope conjugates for vaccination against obesity and excess body fat increase or loss in human and animal

IN Boving, Tine Elisabeth Gottschalk; Klysner, Steen

PA Pharmexa A/S, Den.

SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024183	A1	20040325	WO 2003-DK592	20030912 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2498739	A1	20040325	CA 2003-2498739	20030912 <--
	AU 2003263150	A1	20040430	AU 2003-263150	20030912 <--
	EP 1539232	A1	20050615	EP 2003-794825	20030912 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1694724	A	20051109	CN 2003-825086	20030912 <--
	JP 2006504413	T	20060209	JP 2004-535024	20030912 <--
	MX 2005PA02699	A	20050920	MX 2005-PA2699	20050310 <--
	IN 2005KN00485	A	20060623	IN 2005-KN485	20050323 <--
	NO 2005001779	A	20050411	NO 2005-1779	20050411 <--
	ZA 2005002929	A	20060222	ZA 2005-2929	20050411 <--
PRAI	DK 2002-1345	A	20020912 <--		
	US 2002-410164P	P	20020912 <--		
	WO 2003-DK592	W	20030912 <--		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Inhalation compositions containing buffers and anti-inflammatory agents

AB Bronchodilating concs. and diluted compns., methods of use thereof, and processes for making the concs. and diluted compns., are provided. The compns. are intended for administration as a nebulized aerosol. Methods for treatment, prevention, or amelioration of one or more symptoms of

bronchoconstrictive disorders using the compns. provided herein are also provided. Thus, a composition contained Fluticasone propionate 150 μg/mL, TPGS 4, propylene glycol 1.67, glycerin 2, NaCl 0.1, and water 92.1% by weight, and buffer 2 mM.

AN 2004:100805 HCAPLUS <<LOGINID::20080702>>

DN 140:151959

TI Inhalation compositions containing buffers and anti-inflammatory agents

IN Banerjee, Partha S.; Malladi, Ramana R.; Chaudry, Imtiaz A.

PA Dey, L.P., USA

SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20040023935	A1	20040205	US 2002-212573	20020802 <--
PRAI US 2002-212573		20020802	<--	

L16 ANSWER 8 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Medical goods comprising heparin or chitosan-based hemocompatible coating

AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

AN 2003:913055 HCAPLUS <<LOGINID::20080702>>

DN 139:399770

TI Medical goods comprising heparin or chitosan-based hemocompatible coating

IN Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato

PA Hemoteq G.m.b.H., Germany

SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003094990	A1	20031120	WO 2003-DE1253	20030415 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	DE 10221055	A1	20031127	DE 2002-10221055	20020510	<--
	DE 10221055	B4	20071025			
	DE 10261986	A1	20040318	DE 2002-10261986	20020510	<--
	DE 10261986	B4	20080131			
	AU 2003240391	A1	20031111	AU 2003-240391	20030415	<--
	AU 2003240391	B2	20070517			
	CA 2484269	A1	20031120	CA 2003-2484269	20030415	<--
	CN 1543362	A	20041103	CN 2003-800770	20030415	<--
	EP 1501565	A1	20050202	EP 2003-729829	20030415	<--
	EP 1501565	B1	20061102			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
	BR 2003011446	A	20050315	BR 2003-11446	20030415	<--
	CN 1665554	A	20050907	CN 2003-815926	20030415	<--
	JP 2005534724	T	20051117	JP 2004-503070	20030415	<--
	AT 344064	T	20061115	AT 2003-729829	20030415	<--
	ES 2276065	T3	20070616	ES 2003-729829	20030415	<--
	NZ 536331	A	20070831	NZ 2003-536331	20030415	<--
	IN 2004MN00606	A	20050218	IN 2004-MN606	20041028	<--
	ZA 2004008791	A	20050527	ZA 2004-8791	20041028	<--
	ZA 2004008757	A	20050531	ZA 2004-8757	20041028	<--
	US 20050176678	A1	20050811	US 2004-513982	20041108	<--
	MX 2004PA11112	A	20050714	MX 2004-PA11112	20041109	<--
	IN 2005MN01451	A	20070706	IN 2005-MN1451	20051230	<--
PRAI	US 2002-378676P	P	20020509	<--		
	DE 2002-10221055	A	20020510	<--		
	WO 2003-DE1253	W	20030415	<--		
	IN 2004-MN606	A3	20041028			

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Nanoparticulate compositions of angiogenesis inhibitors
AB Nanoparticulate compns. comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compns. have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compns. For example, a nanoparticulate dispersion was prepared by milling a mixture containing 5% 2-methoxyestradiol, 1% hydroxypropyl cellulose of low viscosity (HPC-SL), and 0.05% docusate sodium (DOSS). The mean particle size of the nanoparticulate dispersion of 2-methoxyestradiol was 153 nm, with 50% < 144 nm, 90% < 217 nm, and 95% < 251 nm. After 2 wk storage at 5°, the nanoparticulate dispersion of 2-methoxyestradiol had a mean particle size of 195 nm.
AN 2003:777565 HCAPLUS <<LOGINID::20080702>>
DN 139:296972
TI Nanoparticulate compositions of angiogenesis inhibitors
IN Merisko-Liversidge, Elaine; Bosch, H. William; Cary, Greta G.; Pruitt, John; Ryde, Tuula; Jain, Rajeev; Walters, Amy
PA Elan Pharma International Ltd., USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003080027	A1	20031002	WO 2003-US8546	20030320	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,					

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2479665          A1     20031002    CA 2003-2479665         20030320 <--
    AU 2003230691       A1     20031008    AU 2003-230691          20030320 <--
    US 20040033267      A1     20040219    US 2003-392403          20030320 <--
    EP 1490030          A1     20041229    EP 2003-723781          20030320 <--
    EP 1490030          B1     20061025
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    JP 2005530712       T      20051013    JP 2003-577857          20030320 <--
    AT 343376           T      20061115    AT 2003-723781          20030320 <--
    EP 1800666          A1     20070627    EP 2006-22201           20030320 <--
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
           IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
    US 20080050461      A1     20080228    US 2007-928250          20071030 <--
    US 20080107741      A1     20080508    US 2007-928278          20071030 <--
PRAI US 2002-365540P    P      20020320  <--
    US 2002-366542P     P      20020325  <--
    EP 2003-723781      A3     20030320  <--
    US 2003-392403      A3     20030320  <--
    WO 2003-US8546      W      20030320  <--
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 10 OF 23  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Effect of amphotericin B treatment on kinetics of cytokines and parameters
     of fungal load in neutropenic rats with invasive pulmonary aspergillosis
AB   The kinetics of various parameters of fungal load and cytokines were
     investigated, to acquire insight into the pathogenesis of invasive
     pulmonary aspergillosis (IPA) during antifungal treatment with
     amphotericin B.  Neutropenic rats with left-sided IPA received either
     treatment with amphotericin B or remained untreated.  At 0, 4, 8, 16, 24,
     48, 72 and 120 h after fungal inoculation, the rats were dissected.  The
     size of the macroscopic pulmonary lesions, the number of cfu and amts. of
     chitin were determined in the infected left lung.  Galactomannan
     concns. were measured both in the left lung and serum.  The cytokines
     tumor necrosis factor (TNF)-α,  interleukin (IL)-1β,
     IL-6, interferon (IFN)-γ, IL-4, IL-10, and the chemokines
     macrophage inflammatory protein (MIP)-2 and monocyte chemoattractant
     protein (MCP)-1 were determined quant. by ELISA in the infected left lung,
     uninfected right lung and serum.  Amphotericin B treatment of IPA resulted
     in changed aspect of pulmonary lesions and significantly reduced levels of
     left lung chitin (72 and 120 h), left lung galactomannan (72 and
     120 h) and serum galactomannan (120 h), but not left lung cfu,
     compared with untreated infected rats.  In addition, amphotericin B treatment
     resulted in a significant decrease in levels of left lung IL-6 (at 72 and
     120 h), MIP-2 (at 120 h) and MCP-1 (at 120 h).  No local or systemic
     increases in TNF-α, IL-1β or IFN-γ were observed during
     infection.  It is concluded that treatment with amphotericin B results in
     decreased fungal load in the infected lung.  This reduction in fungal load
     probably results in a decreased local inflammatory response, as measured
     by decreased levels of IL-6, MIP-2 and MCP-1 in the infected lung.
AN   2003:726072  HCAPLUS <<LOGINID::20080702>>
DN   140:122139
```

TI Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis
AU Becker, Martin J.; de Marie, Siem; Fens, Marcel H. A. M.; Verbrugh, Henri A.; Bakker-Woudenberg, Irma A. J. M.
CS Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center Rotterdam, Rotterdam, 3015 GE, Neth.
SO Journal of Antimicrobial Chemotherapy (2003), 52(3), 428-434
CODEN: JACHDX; ISSN: 0305-7453
PB Oxford University Press
DT Journal
LA English
RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Silver-containing antimicrobial compositions
AB The present invention comprises methods and compns. for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compns. for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses. The incorporation of the antimicrobial agent, penicillin G, into the matrix was evaluated by dissolving 1+106 units of penicillin G powder into 50 mL of water. Acrylamide, methylenebisacrylamide, glycerol, and a guar gum/isopropyl alc. mixture were added 900 mL water and mixed for 2 h. The penicillin solution was then added along with TEMED dissolved in 25 mL water. After thorough mixing, ammonium persulfate in 25 mL water was added and mixed thoroughly. The mixture was then poured into sheet molds and allowed to gel. The sheets of semi-solid gel material were stripped from the mold and dehydrated to approx. 7% their original water content for storage. Disks of 0.7 cm diameter were cut from the sheets. These results demonstrate the release of active penicillin G after its incorporation into the matrix.
AN 2003:622578 HCAPLUS <<LOGINID::20080702>>
DN 139:169330
TI Silver-containing antimicrobial compositions
IN Gibbins, Bruce L.; Hopman, Lance D.
PA Acrymed, USA
SO U.S., 29 pp., Cont.-in-part of U.S. Ser. No. 191,223.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6605751	B1	20030812	US 2000-675892	20000929 <--
	US 6355858	B1	20020312	US 1998-191223	19981113 <--
	US 20040010215	A1	20040115	US 2003-441275	20030519 <--
	US 6897349	B2	20050524		
	US 20050226931	A1	20051013	US 2004-978556	20041101 <--
PRAI	US 1997-971074	A2	19971114	<--	
	US 1998-191223	A2	19981113	<--	
	US 1999-157000P	P	19991001	<--	
	US 2000-212455P	P	20000619	<--	
	US 2000-675892	A1	20000929	<--	
	US 2003-441275	A1	20030519	<--	

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Effects of a lichen galactomannan and its vanadyl (IV) complex on peritoneal macrophages and leishmanicidal activity
AB A galactomannan (GMPOLY) isolated from lichen Ramalina celastri was complexed with vanadyl ion (IV;VO) forming the complex GMPOLY-VO. Both GMPOLY and GMPOLY-VO diminished the superoxide anion production by macrophages triggered with PMA, the complex giving rise to this effect at concns. 100 times lower than GMPOLY. Macrophages treated with GMPOLY enhanced the nitric oxide production (40%), this effect not being observed when interferon-γ (IFN-γ) or IFN-γ plus lipopolysaccharide (LPS) were present. No effect on nitric oxide production was observed by treatment of macrophage with GMPOLY-VO. Both GMPOLY and GMPOLY-VO exhibited leishmanicidal effects on the amastigote form of Leishmania amazonesis, but only GMPOLY-VO inhibited the growth of promastigote form.
AN 2002:543306 HCAPLUS <<LOGINID::20080702>>
DN 137:92613
TI Effects of a lichen galactomannan and its vanadyl (IV) complex on peritoneal macrophages and leishmanicidal activity
AU Noleto, Guilhermina R.; Merce, Ana Lucia R.; Iacomini, Marcello; Gorin, Philip A. J.; Soccol, Vanete Thomaz; Oliveira, Maria Benigna M.
CS Departamento de Bioquimica, Universidade Federal do Parana, Curitiba, Brazil
SO Molecular and Cellular Biochemistry (2002), 233(1&2), 73-83
CODEN: MCBIB8; ISSN: 0300-8177
PB Kluwer Academic Publishers
DT Journal
LA English
RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents
AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for the treatment of wounds. The incorporation of the antimicrobial agent, penicillin G, into the matrix was evaluated by dissolving 1+106 units of penicillin G powder into 50 mL water. Acrylamide, methylenebisacrylamide, glycerol, and a guar gum/isopropyl alc. mixture were mixed for 2 h. The penicillin solution was then added to an aqueous solution of TEMED and after thorough mixing, ammonium persulfate in water was added and mixed thoroughly. The mixture was then poured into sheet molds and allowed to gel. The sheets of semi-solid gel material were stripped from the mold and dehydrated to approx. 7% their original water content for storage. Prior to testing, the sheets were placed in a humidified environment until the sheet weight had increased to approx. 118-122% the storage weight Disks were cut and placed onto the surfaces of agar plates that had previously been seeded with various strains of microorganisms (Staphylococcus aureus; Escherichia coli; Candida albicans; Pseudomonas aeruginosa). Zones of inhibition were measured around the penicillin containing matrix but not the control matrix on the S. aureus, E. coli, and P. aeruginosa plates. The results demonstrated the release of active penicillin G after its incorporation into the matrix.
AN 2002:182217 HCAPLUS <<LOGINID::20080702>>
DN 136:236843
TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents

IN Gibbins, Bruce L.
PA AcryMed, Inc., USA
SO U.S., 14 pp., Cont.-in-part of U.S. 5,928,174.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355858	B1	20020312	US 1998-191223	19981113 <--
	US 6605751	B1	20030812	US 2000-675892	20000929 <--
	US 20040010215	A1	20040115	US 2003-441275	20030519 <--
	US 6897349	B2	20050524		
	US 20050226931	A1	20051013	US 2004-978556	20041101 <--
PRAI	US 1997-971074	A2	19971114	<--	
	US 1998-191223	A2	19981113	<--	
	US 1999-157000P	P	19991001	<--	
	US 2000-212455P	P	20000619	<--	
	US 2000-675892	A1	20000929	<--	
	US 2003-441275	A1	20030519	<--	

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 14 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
AB A stable cosmetic, dermatol., or pharmaceutical composition comprising: (a) about 0.001-99.9%, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate, manganese gluconate, nor lithium gluconate; and (b) about 0.1-99.999%, by weight, of a vehicle, wherein the vehicle comprises at least about 5%, by weight of the composition, of propylene glycol. The composition is administered orally, parenterally or topically. For example, a topical composition was prepared containing zinc lactobionate 5.0%, zinc gluconate 3.0%, minoxidil 2.5%, propylene glycol 8.0%, dimethylisosorbide 19.0%, and ethanol and minors up to 100%.
AN 2002:89809 HCAPLUS <<LOGINID::20080702>>
DN 136:139844
TI Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
IN Gardlik, John Michael; Severynse-Stevens, Diana; Comstock, Bryan Gabriel
PA The Procter & Gamble Company, USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002007700	A2	20020131	WO 2001-US23425	20010725 <--
	WO 2002007700	A8	20031030		
	WO 2002007700	A3	20020829		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,

KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US	20020119174	A1	20020829	US 2001-909440	20010719 <--
PRAI US	2000-220756P	P	20000726	<--	

L16 ANSWER 15 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Method of regulating hair growth using metal complexes of oxidized carbohydrates

AB A method for regulating the growth of hair comprising administering to a mammal, an effective amount of a composition comprising: (a) about 0.001-99.9%, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate; and (b) about 0.1-99.999%, by weight, of a vehicle. The composition is administered orally, parenterally, or topically. For example, a topical composition contained zinc lactobionate 5.0%, zinc gluconate 1.0%, zinc pyrithione 1.0%, Tween 20 1.0%, propylene glycol 10.0%, dimethylisosorbide 18.0%, EtOH 30.0%, and water and minors up to 100%. Also, tablets were prepared containing zinc lactobionate 100 mg, Crospovidone 15
mg, lactose 200 mg, microcryst. cellulose 80 mg, and magnesium stearate 5 mg.

AN 2002:89795 HCAPLUS <<LOGINID::20080702>>

DN 136:139843

TI Method of regulating hair growth using metal complexes of oxidized carbohydrates

IN Gardlik, John Michael; Severynse-Stevens, Diana; Comstock, Bryan Gabriel

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002007685	A2	20020131	WO 2001-US23424	20010725 <--
WO 2002007685	A8	20031030		
WO 2002007685	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020035070	A1	20020321	US 2001-909441	20010719 <--
AU 2001080779	A5	20020205	AU 2001-80779	20010725 <--
PRAI US 2000-220755P	P	20000726	<--	
WO 2001-US23424	W	20010725	<--	

L16 ANSWER 16 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Silver-containing compositions, devices and methods for making them

AB The present invention comprises methods and comps. for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and comps. for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gelable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.

AN 2001:265285 HCAPLUS <<LOGINID::20080702>>
DN 134:300843
TI Silver-containing compositions, devices and methods for making them
IN Gibbins, Bruce L.; Hopman, Lance D.
PA Acrymed, USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001024839	A1	20010412	WO 2000-US26890	20000929 <--
	WO 2001024839	A9	20021114		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1216065	A1	20020626	EP 2000-970522	20000929 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1999-157000P	P	19991001	<--	
	US 2000-212455P	P	20000619	<--	
	WO 2000-US26890	W	20000929	<--	

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Immunoglobulin production regulating activity of dietary fibers
AB In rats fed some types of dietary fat, class specific increases or decreases of serum Igs (lg), changes in lg productivity of spleen and mesenteric lymph node (MLN) lymphocytes, changes in T cell populations of splenocytes, and changes in cytokine productivity in MLN lymphocytes have been reported. In comparison with the water-insol. dietary fiber cellulose the soluble forms pectin, glucomannan and chitosan enhanced the production of IgA and IgG, but inhibit the production of IgE. The proportion of CD8 cells in rats fed these dietary fibers are significantly lower than rats fed cellulose and the proportion of CD4 cells is significantly elevated. In addition, production of interferon-γ and tissue necrosis factor-α by MLN lymphocytes is significantly enhanced by pectin as compared with cellulose. These results suggest that dietary fibers in the diet affect Ig production by influencing T cell differentiation and cytokine synthesis. Though similar Ig production regulating activity is observed galactomannan guar gum, enzymically degraded guar gum exerts lower activity. When MLN lymphocytes are cultured in the presence of glucomannan, galactomannan, or their structural sugars, no change in the Ig productivity has been observed These results suggest that the above effects are not due to the direct interaction of dietary fibers or their metabolites on the Ig production system.
AN 2000:418862 HCAPLUS <<LOGINID::20080702>>
DN 133:281020
TI Immunoglobulin production regulating activity of dietary fibers
AU Yamada, Koji
CS Lab. Food Chem., Div. Bioresource Bioenvironmental Sci., Grad. Sch. Kyushu

Univ., Fukuoka, 812-8581, Japan
SO Foods & Food Ingredients Journal of Japan (2000), 186, 26-32
CODEN: FFIJER; ISSN: 0919-9772
PB FFI Janaru
DT Journal
LA Japanese

L16 ANSWER 18 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Improved wound dressing device and methods
AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for treatment of wounds. A mixing tank was charged with 161.4 kg water and 9.1894 kg acrylamide, and 0.10347 kg of methylenebisacrylamide and 9.3046 kg glycerol were added and mixed. Then, 1.0213 kg guar gum was dispersed in a mixture containing 0.9770 kg isopropanol and 2 kg water. The solution of guar gum was dispersed into the acrylamide mixture After suitable mixing, 0.1042 kg TEMED was added and polymerization was catalyzed with 0.0999 kg ammonium persulfate. While
the batch was still liquid, it was poured into molds to form sheets. After gelling had occurred, sheets were transferred to a desiccator and dehydrated to form a stable sheet.
AN 1999:350613 HCAPLUS <<LOGINID::20080702>>
DN 130:357215
TI Improved wound dressing device and methods
IN Gibbins, Bruce L.
PA USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925395	A2	19990527	WO 1998-US24272	19981113 <--
	WO 9925395	A3	19990812		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9916991	A	19990607	AU 1999-16991	19981113 <--
	EP 1030695	A2	20000830	EP 1998-961733	19981113 <--
	EP 1030695	B1	20050406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 292481	T	20050415	AT 1998-961733	19981113 <--
PRAI	US 1997-971074	A2	19971114	<--	
	WO 1998-US24272	W	19981113	<--	

L16 ANSWER 19 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
AB Gas and gaseous precursor filled microspheres, and foams provide novel topical and s.c. delivery vehicles for various active ingredients,

including drugs and cosmetics. Gas and gaseous precursor filled microcapsules were prepared from dipalmitoylphosphatidylcholine.

AN 1998:207280 HCAPLUS <<LOGINID::20080702>>

DN 128:275101

OREF 128:54369a,54372a

TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles

IN Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David

PA Imarx Pharmaceutical Corp., USA

SO U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 307,305.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5733572	A	19980331	US 1994-346426	19941129	<--
	US 5088499	A	19920218	US 1990-569828	19900820	<--
	WO 9109629	A1	19910711	WO 1990-US7500	19901219	<--
	W: CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE					
	JP 05502675	T	19930513	JP 1991-503276	19901219	<--
	JP 3309356	B2	20020729			
	AT 180170	T	19990615	AT 1991-902857	19901219	<--
	ES 2131051	T3	19990716	ES 1991-902857	19901219	<--
	CA 2069759	C	20070116	CA 1990-2069759	19901219	<--
	US 5228446	A	19930720	US 1991-717084	19910618	<--
	WO 9222247	A1	19921223	WO 1992-US2615	19920331	<--
	W: AU, CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE					
	AU 9220020	A	19930112	AU 1992-20020	19920331	<--
	AU 667471	B2	19960328			
	JP 06508364	T	19940922	JP 1993-500847	19920331	<--
	JP 3456584	B2	20031014			
	EP 616508	A1	19940928	EP 1992-912456	19920331	<--
	EP 616508	B1	20010718			
	EP 616508	B2	20040929			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE					
	AT 203148	T	20010815	AT 1992-912456	19920331	<--
	ES 2159280	T3	20011001	ES 1992-912456	19920331	<--
	CA 2110491	C	20070724	CA 1992-2110491	19920331	<--
	US 5469854	A	19951128	US 1993-76239	19930611	<--
	US 5580575	A	19961203	US 1993-76250	19930611	<--
	US 5348016	A	19940920	US 1993-88268	19930707	<--
	US 5542935	A	19960806	US 1993-160232	19931130	<--
	US 5585112	A	19961217	US 1993-159687	19931130	<--
	US 5769080	A	19980623	US 1994-199462	19940222	<--
	WO 9428874	A1	19941222	WO 1994-US5633	19940519	<--
	W: AU, CA, CN, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	US 5773024	A	19980630	US 1994-307305	19940916	<--
	CA 2177713	A1	19950608	CA 1994-2177713	19941130	<--
	WO 9515118	A1	19950608	WO 1994-US13817	19941130	<--
	W: AU, CA, CN, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 740528	A1	19961106	EP 1995-908414	19941130	<--
	EP 740528	B1	20030326			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	JP 09506098	T	19970617	JP 1995-515763	19941130	<--
	AT 235228	T	20030415	AT 1995-908414	19941130	<--
	US 5571497	A	19961105	US 1995-468056	19950606	<--

CN	1180310	A	19980429	CN 1996-193069	19960327 <--
CN	1102045	B	20030226		
US	6001335	A	19991214	US 1996-665719	19960618 <--
US	5935553	A	19990810	US 1996-758179	19961125 <--
US	6743779	B1	20040601	US 1997-841169	19970429 <--
US	5985246	A	19991116	US 1997-888426	19970708 <--
AU	9856271	A	19980507	AU 1998-56271	19980224 <--
AU	713127	B2	19991125		
AU	9888405	A	19981203	AU 1998-88405	19981012 <--
AU	731072	B2	20010322		
HK	1013625	A1	20000420	HK 1998-114978	19981223 <--
AU	9910043	A	19990304	AU 1999-10043	19990104 <--
GR	3036877	T3	20020131	GR 2001-401740	20011011 <--
PRAI US	1989-455707	B2	19891222	<--	
US	1990-569828	A2	19900820	<--	
US	1991-716899	B2	19910618	<--	
US	1991-717084	A2	19910618	<--	
US	1993-76239	A2	19930611	<--	
US	1993-76250	A2	19930611	<--	
US	1993-159674	B2	19931130	<--	
US	1993-159687	A2	19931130	<--	
US	1993-160232	A2	19931130	<--	
US	1994-307305	A2	19940916	<--	
WO	1990-US7500	W	19901219	<--	
US	1991-716793	A	19910618	<--	
US	1991-750877	A3	19910826	<--	
US	1992-818069	A3	19920108	<--	
WO	1992-US2615	A	19920331	<--	
US	1992-967974	A3	19921027	<--	
US	1993-17683	A3	19930212	<--	
US	1993-18112	B3	19930217	<--	
US	1993-85608	A3	19930630	<--	
US	1993-88268	A3	19930707	<--	
US	1993-163039	A3	19931206	<--	
US	1994-212553	B2	19940311	<--	
AU	1994-70416	A3	19940519	<--	
US	1994-346426	A	19941129	<--	
AU	1995-21850	A3	19941130	<--	
WO	1994-US13817	W	19941130	<--	
US	1995-395683	A3	19950228	<--	
US	1995-468056	A3	19950606	<--	
US	1995-471250	A3	19950606	<--	
US	1996-640554	B2	19960501	<--	
US	1996-665719	A3	19960618	<--	
US	1997-785661	B2	19970117	<--	

RE.CNT 314 THERE ARE 314 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Glucoamylase gene fusions alleviate limitations for protein production in Aspergillus awamori at the transcriptional and (post) translational levels

AB In this study we have analyzed the effects of a glucoamylase gene fusion on the mRNA levels and protein levels for the human interleukin -6 gene (hil6) and the guar α-galactosidase gene (aglA). Previously it was shown that production of nonfused α-galactosidase and hIL-6 in Aspergillus awamori was limited at transcriptional and (post) translational levels, resp. (R. J. Gouka, P. J. Punt, J. G. M. Hessing, and C. A. M. J. J. van den Hondel, Appl. Environ. Microbiol. 62:1951-1957, 1996). Vectors were constructed which contained either the hil6 or aglA gene fused to the Aspergillus niger glucoamylase gene (glaA) under control of the efficient 1,4-γ-endoxylanase A promoter and transcription

terminator. For comparison, the vectors were integrated in a single copy at the pyrG locus of A. awamori. A glaA fusion to the 5' end of the hil6 gene resulted in a large increase in hIL-6 yield, whereas with a glaA fusion to the 3' end of the hil6 gene, almost no protein was produced. Nevertheless, the steady-state mRNA levels of both fusions were very similar and not clearly increased compared to those of a strain expressing nonfused hIL-6. Fusions of glaA to the 5' end of the wild-type guar aglA gene resulted in truncated mRNA lacking almost 900 bases (>80%) of the aglA sequence. When the coding sequence of the wild-type aglA gene was replaced by a synthetic aglA gene with optimized Saccharomyces cerevisiae codon usage, full-length mRNA was obtained. Compared to a nonfused synthetic aglA gene, a glaA fusion with the synthetic aglA gene resulted in a 25-fold increase in the mRNA level and, as a consequence, a similar increase in the α-galactosidase protein level. The truncated transcripts derived from the wild-type aglA gene were further analyzed by nuclear run-on transcription assays. These expts. indicated that transcription elongation in the nucleus proceeded at least 400 bases downstream of the site where the truncation was determined, indicating that transcription elongation or premature termination was not the reason for the generation of truncated mRNAs. As the truncated mRNA also contained a poly(A) tail, truncation most likely occurs by incorrect processing of the aglA mRNA in the nucleus.

AN 1997:106774 HCAPLUS <<LOGINID::20080702>>
DN 126:167043
OREF 126:32197a,32200a
TI Glucoamylase gene fusions alleviate limitations for protein production in Aspergillus awamori at the transcriptional and (post) translational levels
AU Gouka, Robin J.; Punt, Peter J.; Van Den Hondel, Cees A.M.J.J.
CS Department of Molecular Genetics and Gene Technology, TNO Nutrition and Food Research Institute, Rijswijk, NL-2280 HV, Neth.
SO Applied and Environmental Microbiology (1997), 63(2), 488-497
CODEN: AEMIDF; ISSN: 0099-2240
PB American Society for Microbiology
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 21 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Analysis of heterologous protein production in defined recombinant Aspergillus awamori strains
AB A study was carried out to obtain more insight into the parameters that determine the secretion of heterologous proteins from filamentous fungi. A strategy was chosen in which the mRNA levels and protein levels of a number of heterologous genes of different origins were compared. All genes were under control of the A. awamori 1,4-β-endoxylanase A (exlA) expression signals and were integrated in a single copy at the A. awamori pyrG locus. A Northern (RNA) anal. showed that large differences occurred in the steady-state mRNA levels obtained with the various genes; those levels varied from high values for genes of fungal origin (A. awamori 1,4-β-endoxylanase A, Aspergillus niger glucoamylase, and Thermomyces lanuginosa lipase) to low values for genes of nonfungal origin (human interleukin 6 and Cyamopsis tetragonoloba [guar] α-galactosidase). With the C. tetragonoloba α-galactosidase wild-type gene, full-length mRNA was undetectable. Surprisingly, small amts. of full-length mRNA could be detected when a C. tetragonoloba α-galactosidase gene with an optimized Saccharomyces cerevisiae preference was expressed. In all cases except human interleukin 6, the protein levels corresponded to the amts. expected on basis of the mRNA levels. For human interleukin 6, very low protein levels were observed, whereas relatively high steady-state mRNA levels were

obtained. These data suggest that intracellular protein degradation is the most likely explanation for the low levels of secreted human interleukin 6.
AN 1996:335305 HCAPLUS <<LOGINID::20080702>>
DN 125:8567
OREF 125:1971a,1974a
TI Analysis of heterologous protein production in defined recombinant Aspergillus awamori strains
AU Gouka, Robin J.; Punt, Peter J.; Hessing, Johanna G. M.; van den Hondel, Cees A. M. J. J.
CS Dep. Mol. Genetics Gene Technol., TNO Nutrition Food Res. Inst., Rijswijk, 2280 HV, Neth.
SO Applied and Environmental Microbiology (1996), 62(6), 1951-1957
CODEN: AEMIDF; ISSN: 0099-2240
PB American Society for Microbiology
DT Journal
LA English

L16 ANSWER 22 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Monocrystalline iron oxide particles for studying biological tissues
AB A liquid that contains monocryst. superparamagnetic particles and a method for preparing this liquid are disclosed. Also described are a method of decreasing the NMR relaxation times of water protons in contact with biol. tissue by using this liquid and an in vitro method for obtaining information from biol. tissue or components thereof using this liquid
AN 1996:184265 HCAPLUS <<LOGINID::20080702>>
DN 124:283285
OREF 124:52347a,52350a
TI Monocrystalline iron oxide particles for studying biological tissues
IN Weissleder, Ralph
PA The General Hospital Corporation, USA
SO U.S., 36 pp., Cont. of U.S. Ser. No. 725,060, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5492814	A	19960220	US 1992-970942	19921103 <--
PRAI US 1992-970942	B1	19921103	<--	
US 1991-725060	B2	19910703	<--	
US 1990-549434		19900706	<--	

L16 ANSWER 23 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI An interferon-like substance induced by mannans
AB An interferon-like substance was detected in the serum of mice 2 hrs. after an i.v. inoculation of mannan (100 γ) obtained from Candida albicans. A galactomannan from Lipomyces starkeyi had a lower interferoninducing ability in cell cultures.
AN 1967:409818 HCAPLUS <<LOGINID::20080702>>
DN 67:9818
OREF 67:1835a,1838a
TI An interferon-like substance induced by mannans
AU Borecky, L.; Lackovic, V.; Blaskovic, Dionyz; Masler, Ladislav; Sikl, Dobroslav
CS Ceskoslov. Akad. Ved., Bratislava, Czech.
SO Arerugi (1967), 11(3), 264-6
CODEN: ARERAM; ISSN: 0021-4884
DT Journal
LA English